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FUNCTIONAL ANALYSIS OF MICRORNA-10b IN BREAST CARCINOMA 
 
ABSTRACT 
 
MicroRNAs (miRNAs) represent a class of small noncoding RNAs that 
regulate gene expression. Recent studies have shown that miRNAs are mis-
expressed in various human cancers and that some miRNAs have the potential 
to act as tumor suppressors or oncogenes. MiR-10b is one miRNA that has been 
shown to be deregulated in breast cancer. However, current findings regarding 
miR-10b’s role in breast cancer are controversial. MiR-10b was originally 
reported to be downregulated in breast cancer compared to normal breast tissue. 
Subsequently, miR-10b was argued to be upregulated in metastatic breast 
cancer cell lines, acting as a potent pro-metastatic agent via regulation of 
HOXD10. This report was soon challenged by another group who reported that 
miR-10b expression in a large patient cohort correlated inversely and significantly 
with tumor size, grade, and vascular invasion, but did not correlate with 
development of distant metastases or survival. These latter data suggest that 
miR-10b may impede specific functions associated with breast cancer 
progression.  
In this thesis, I present my analysis of miR-10b function in breast 
carcinoma cells, which revealed that it suppresses their migration and invasion. 
To define a mechanism that accounts for this suppressive function, I identified T-
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lymphoma invasion and metastasis 1 (TIAM1), a guanine nucleotide exchange 
factor for Rac1, as a miR-10b target and demonstrated that miR-10b inhibits 
TIAM1-dependent Rac1 activation, migration, and invasion. In addition, I 
identified the VEGF receptor fms-related tyrosine kinase 1 (FLT-1) as a second 
target of miR-10b and discovered a novel function for FLT-1 in promoting breast 
carcinoma cell migration and invasion. My results show, for the first time, that 
Rac activation can be regulated by a specific miRNA and provide a novel 
mechanism for the regulation of TIAM1 and FLT-1 in breast cancer. These data 
support the conclusion from clinical data that miR-10b expression correlates 
inversely with breast cancer progression, and suggest that miR-10b functions to 
impede breast carcinoma progression by regulating key target genes involved in 
cell motility. 
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CHAPTER I 
 
INTRODUCTION 
 
Cell motility is essential to many normal cell processes, including 
embryonic morphogenesis, wound healing, and immune-cell trafficking (Friedl 
and Brocker, 2000). The molecular mechanisms of cell migration involve 
continuous cycling of a series of interdependent processes, beginning with 
abrogation of cell-cell contacts and protrusion of the leading edge, followed by 
cell-matrix interaction and formation of focal contacts, the recruitment of surface 
proteases to extracellular matrix (ECM) contacts and localized proteolysis of the 
ECM, cell contraction by actomyosin, and finally detachment of the trailing edge 
(Friedl and Wolf, 2003; Lauffenburger and Horwitz, 1996). These processes are 
regulated by cell-cell matrix adhesion molecules such as integrins, matrix-
degrading enzymes, cell-cell adhesion molecules, and cell-cell communication. In 
addition, factors within the microenvironment, including chemokines and growth 
factors such as epidermal growth factor (EGF) and lysophosphatidic acid (LPA), 
can propel, direct, and regulate cell motility. These motility-inducing factors 
promote cell migration by promigratory signal transduction via phosphatidyl-
inositol 3-kinase (PI3K) and Rho GTPases Rac and Rho (Friedl and Wolf, 2003). 
Tumor cells are believed to use similar, if not identical, mechanisms of 
migration to those that occur in normal cells (Friedl and Brocker, 2000). The 
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aberrant activation of these motility pathways – a dominance of promigratory 
events in the absence of counteracting stop signals (Alper et al., 2001; Giannelli 
et al., 1997) – is an essential feature of the metastatic process (Gupta and 
Massague, 2006). 
The processes involved in carcinoma progression include tumor cell 
migration and invasion of surrounding tissues, and a “metastatic cascade,” in 
which a carcinoma cell acquires the ability to escape from the tumor mass, 
penetrate tumor blood vessels or local lymphatics, disseminate through the 
vasculature, extravasate from the vessels, colonize distant organs, and expand 
to form metastases (Liotta et al., 1991). The ability of carcinoma cells to invade 
surrounding tissues requires altered cell adhesion, loss of cell polarization, 
cytoskeletal rearrangement, and basement membrane remodeling (Sahai and 
Marshall, 2002). In preventing metastatic disease, the processes of local invasion 
and metastatic spread are the most clinically relevant, yet they remain the most 
poorly understood at the molecular level. Thus, identifying the mechanisms by 
which tumor cells acquire such invasive and metastatic potential is critical for 
developing strategies to impair cancer progression in a clinical setting (Chambers 
et al., 2002).  
Proposed mechanisms of metastatic spread include the epithelial-to-
mesenchymal transition (EMT), a phenotype switch in which tumors cells with a 
highly differentiated epithelial morphology assume a migratory and invasive 
phenotype, and collective migration, in which a group of tumor cells metastasize 
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together (Christiansen and Rajasekaran, 2006). The EMT involves changes in 
gene expression, distribution, and function of growth factors, transcription factors, 
cell-to-cell adhesion molecules, cell-to-ECM adhesion molecules, cytoskeletal 
modulators, and extracellular proteases - the same elements commonly 
associated with cancer progression (Thompson et al., 2005). These critical 
elements lead to changes in tumor microenvironment, cell adhesion, and the cell 
signaling pathways that regulate cell motility (Christofori, 2006; Liotta and Kohn, 
2001). Significant overlap exists between migration and invasion pathways. An 
understanding of the ability of a carcinoma cell to acquire the migratory and 
invasive capabilities that lead to metastatic disease is a key area for identifying 
mechanisms of cancer progression and preventing metastasis in a clinical 
setting.   
 
MICRORNAs 
MicroRNAs (miRNAs) are a recently discovered class of regulatory RNAs 
that provide an attractive model for global gene regulation during breast cancer 
progression (Tavazoie et al., 2008). MiRNAs are small, single stranded, 
noncoding RNAs that function to regulate protein expression levels from protein 
coding RNAs (Bartel, 2004). MiRNAs were discovered following the observation 
that the lin-4 gene, essential for development of the nematode worm C. elegans, 
does not encode protein. Instead the gene product is a small RNA that acts as a 
negative regulator of another critical gene, lin-14, by binding to the 3’ 
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untranslated region (UTR) of the lin-14 transcript, and thereby inhibiting its 
translation (Lee et al., 1993; Wightman et al., 1993).  
MiRNAs are transcribed from the genome as primary transcripts that are 
extensively processed to produce mature, functional miRNAs (Esquela-Kerscher 
and Slack, 2006) (Figure 1). In humans, miRNA genes are transcribed by RNA 
polymerase II to produce capped and polyadenylated primary transcripts, termed 
‘pri-miRNAs’ (Lee et al., 2002). These miRNA precursors contain stem-loop 
structures in which the bases in each molecule pair internally and often 
imperfectly. The stem-loop structures are necessary for correct processing by the 
RNAse III endonuclease Drosha and its co-factor DGCR8. Drosha and DGCR8 
cleave the loose ends of pri-miRNAs near the base of the stem loop to liberate 
~60-nucleotide pre-miRNA stem-loops (Basyuk et al., 2003; Cai et al., 2004; 
Denli et al., 2004; Gregory et al., 2004; Lee et al., 2003; Lee et al., 2002; Lee et 
al., 2004; Zeng and Cullen, 2003). Pre-miRNAs are exported from the nucleus by 
exportin and Ran-GTP, and further processed in the cytoplasm by another 
RNAse III enzyme, Dicer, to ~22 nt double-stranded siRNA-like imperfect 
duplexes composed of the mature miRNA and a similar-sized fragment obtained 
from the opposing arm of the pre-miRNA (Bagga et al., 2005; Grishok et al., 
2001; Hutvagner et al., 2001; Ketting et al., 2001). The fragment from the 
opposing arm, termed the miRNA* strand, is often peeled away and degraded 
when the miRNA strand of the miRNA:miRNA* duplex is loaded into the RNA-
induced silencing complex (RISC) (Filipowicz et al., 2008; Kim and Kim, 2007).  
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Prevailing models suggest there are two mechanisms by which miRNAs 
regulate the function of their target mRNAs. The RISC complex can combine with 
either the 3’UTR or the open reading frame (ORF) of the target mRNA based on 
the complementarity of the miRNA sequence to the target. Binding to the 3’UTR 
seems to require only imperfect complementarity, specifically conserved Watson-
Crick pairing to the 5’ region of the miRNA centered on nucleotides 2-7, the 
miRNA “seed” (Bartel, 2009). Binding with insufficient complementarity often 
results in translational repression of the target mRNA. On the other hand, binding 
within the ORF requires perfect or near-perfect complementarity, resulting in 
mRNA cleavage and degradation of the mRNA by Argonaute 2 (Ago2), a 
catalytic endonuclease component of RISC (Meister et al., 2004).  Both 
mechanisms ultimately result in downregulation of protein expression from target 
genes. Recent findings indicate rare alternative mechanisms also exist, including 
targeting to the 5’UTR (Orom et al., 2008) and degradation of target mRNAs 
having only partial complementarity to their regulatory miRNAs. Although several 
mechanisms of regulation exist, 3’UTR targeting appears to occur most 
frequently and most effectively, followed by endogenous ORF targeting, and 
finally, 5’UTR targeting (Bartel, 2009). Human miRNAs are thought to use 
primarily the first mechanism of regulation by 3’UTR targeting leading to 
translational repression (Bartel, 2004; Esquela-Kerscher and Slack, 2006). 
 Each individual miRNA has the potential to regulate multiple mRNAs 
(John et al., 2004; Kiriakidou et al., 2004; Krek et al., 2005; Lewis et al., 2003; 
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Lim et al., 2005; Rajewsky and Socci, 2004; Rehmsmeier et al., 2004). Similarly, 
each mRNA is believed to be targeted by several different miRNAs (Pillai, 2005). 
As a result, miRNAs provide an attractive model for global regulation of gene 
expression. In fact, these regulatory molecules have been implicated in an 
increasing number of biological processes, including the development and 
progression of cancer (Calin et al., 2002; Cimmino et al., 2005; Johnson et al., 
2005; Michael et al., 2003; Takamizawa et al., 2004). Recent studies have shown 
that certain miRNAs are deregulated in cancer (Calin and Croce, 2006; Calin et 
al., 2005; Iorio et al., 2005; Lu et al., 2005), and that they can influence key cell 
biological processes that affect tumor progression, including migration, invasion, 
epithelial to mesenchymal transition (Burk et al., 2008; Korpal et al., 2008) and 
metastasis (Huang et al., 2008; Tavazoie et al., 2008; Zhu et al., 2008). MiR-10b 
is one such miRNA.  
MiR-10b 
 MiRNA microarray profiling of 76 primary breast tumors and 10 normal 
breast tissue samples revealed that miR-10b was significantly downregulated in 
breast cancer, and identified miR-10b as one of 15 miRNAs in a signature that 
was able to correctly predict the nature of a breast tissue sample (i.e. normal vs. 
tumor) (Iorio et al., 2005). These results suggested that miR-10b may have a role 
in breast cancer suppression. However, another group suggested the opposite 
conclusion two years later, proclaiming miR-10b to be a pro-metastatic miRNA 
(Ma et al., 2007). In human breast cell lines and mouse xenograft models of 
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breast cancer, miR-10b was found to be highly expressed only in metastatic cells 
and to promote cancer cell invasion and metastasis in vivo (Ma et al., 2007). 
Furthermore, it was reported that the metastasis-promoting transcription factor 
Twist (Yang et al., 2004) binds to the putative miR-10b promoter, thereby 
enhancing transcription of the mir-10b gene. In turn, miR-10b was reported to 
repress HoxD10 directly by binding to its 3’UTR and inhibiting translation. RhoC, 
an important mediator of cell migration and metastasis (Bellovin et al., 2006; 
Clark et al., 2000; Hakem et al., 2005; Kleer et al., 2006; Kondo et al., 2004) that 
is known to be repressed by HoxD10 (Myers et al., 2002), was reported to be 
elevated in miR-10b-expressing cells, providing a mechanism for increased cell 
migration and invasion. Finally, miR-10b expression in a small group of primary 
breast tumors was reported to correlate significantly with clinical progression (Ma 
et al., 2007).  
 Interestingly, the above findings on miR-10b and metastasis were 
challenged soon after when a third group found no significant association 
between miR-10b expression and metastasis or prognosis by real-time PCR 
(Gee et al., 2008). Using fresh frozen samples and long term follow-up data from 
219 patients with early breast cancer, they reported lower expression levels of 
miR-10b in patients without metastases than in normal breast tissue; supporting 
the original finding that miR-10b is downregulated in breast cancer. In direct 
contradiction to the Ma et al. study (2007), miR-10b expression was reported to 
correlate inversely with tumor size and grade. Furthermore, there was no 
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significant correlation between miR-10b and metastasis outcome (Gee et al., 
2008). Collectively, these studies suggest that much work needs to be done 
before drawing conclusions about the function of miR-10b in breast cancer.  
 While miRNAs such as miR-10b have the capacity to regulate a large 
number of genes simultaneously, disrupting the miRNA regulation of a single 
target can have significant phenotypic effects (Bartel, 2007). Among the 
predicted targets of miR-10b in TargetScan, a computational algorithm that 
predicts biological targets of miRNAs by searching for the presence of conserved 
8mer and 7mer 3’UTR sites that match the seed region of each miRNA  (Lewis et 
al., 2005), two genes - TIAM1 and FLT-1 - have been previously implicated in 
breast cancer progression and metastasis. It is possible that these genes may 
promote breast carcinoma progression as part of a miR-10b-regulated pathway. 
 
TIAM1 
 The guanosine triphosphatases (GTPases) Rho, Rac (Ras-related C3 
botulinum toxin substrate 1), and Cdc42 (cell division cycle 42) are members of 
the Rho family, a subset of the Ras superfamily (Rossman et al., 2005; Schmitz 
et al., 2000).These proteins function as molecular switches and play a role in 
many cellular processes, including regulation of the actin cytoskeleton, cell cycle 
progression, gene transcription, and cellular adhesion (Ridley, 2001). In addition, 
mutations and aberrant regulation of these proteins have been implicated in 
tumorigenesis (Advani and Pendergast, 2002; Engers et al., 2000; Kourlas et al., 
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2000; Malliri et al., 2002; Sahai and Marshall, 2002). Rho family proteins are 
active only when bound to GTP and although all possess weak intrinsic GTPase 
activity, their activity level is tightly controlled by three general classes of 
proteins: GTPase-activating proteins (GAPs), guanine nucleotide dissociation 
inhibitors (GDIs), and guanine nucleotide exchange factors (GEFs) (Figure 2). 
GAPs function to enhance the ability of the GTPase to hydrolyze GTP to GDP, 
thereby controlling the rate of movement from the active conformation to the 
inactive conformation. GDIs serve as an anchor by forming a large complex with 
the Rho protein helping to prevent diffusion within the membrane and into the 
cytosol, allowing for spatial control of Rho activation. Finally, GEFs facilitate the 
exchange of GDP for GTP, thereby enhancing Rho activation (Ellenbroek and 
Collard, 2007).  
 One of the most studied GEFs that regulates Rho family GTPases is T-
lymphoma invasion and metastasis gene 1 (TIAM1). TIAM1 was originally 
identified by proviral tagging and in vitro selection for invasiveness from murine 
lymphoma cells in 1994 (Habets et al., 1994). The human homologue was 
identified one year later (Habets et al., 1995). TIAM1 is a member of Dbl family of 
GEFs and acts as an exchange factor for the Rho GTPases Rac1 and Cdc42, 
and to a lesser extent, RhoA (Michiels et al., 1995). TIAM1 induces extensive 
cellular ruffling in fibroblasts via Rac1, in a process independent of RhoA 
(Michiels et al., 1995). In addition, TIAM1 induces invasion of T-lymphoma cells 
into a fibroblast monolayer, as do constitutively active Rac1 and Cdc42. RhoA 
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potentiates invasion and is required for an invasive phenotype, but is not 
sufficient (Stam et al., 1998). Other studies have shown that RhoA can also 
function to impede cell invasion in invasive breast carcinoma due to a reciprocal 
relationship between RhoA and Rac1 activation (Simpson et al., 2004). 
Furthermore, TIAM1 overexpression in neuroblastoma cells promotes cell 
spreading and adhesion, as well as neurite outgrowth. These events are 
dependent on Rac1 and the cells fail to respond to processes driven by Rho, 
such as LPA-induced neurite retraction and cell rounding. Collectively, these 
findings suggest that TIAM1 plays a role in cytoskeletal rearrangement during 
cell migration and that Rho may oppose TIAM1-induced activation of Rac1. In 
fact, TIAM1-induced effects are abrogated by co-expression of constitutively 
active Rho, suggesting a delicate balance between Rac and Rho signaling 
(Leeuwen et al., 1997).  
 Several studies have suggested that TIAM1 induces cellular adhesion, as 
opposed to cellular migration. For example, TIAM1 is reported to concentrate at 
adherens junctions in canine kidney epithelial cells. Ectopic expression of TIAM1 
or constitutively active Rac1 inhibits scattering of these cells by increasing E-
cadherin-mediated cell-cell adhesion and polymerizing actin at cell-cell contacts. 
In Ras-transformed epithelial cells, expression of TIAM1 reverses the fibroblast-
like morphology to an epithelial-like phenotype (Hordijk et al., 1997). Similarly, 
TIAM1 expression in renal cell carcinoma cell lines correlates inversely with 
invasive potential, and overexpression of TIAM1 or constitutively active Rac1 in 
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these cells inhibits cell migration by promoting E-cadherin-mediated adhesion 
(Engers et al., 2001; Engers et al., 2000). Thus, TIAM1’s effects are thought to 
be cell-type specific, increasing motility in mesenchymal cell types and increasing 
cellular adhesion in epithelial cells. In addition, TIAM1/Rac-induced cellular 
response is dependent on the cell substrate (Sander et al., 1998b). For example, 
on fibronectin and laminin 1, Tiam1/Rac signaling inhibits migration by restoring 
E-cadherin-mediated cell-cell adhesion. However, on different collagens, 
formation of E-cadherin adhesions is prevented and expression of Tiam1 
promotes cell motility. The status of Rac and Rho activation may also be critical 
to the effects of TIAM1. As TIAM1 acts as a GEF for both of these GTPases, 
different levels of activation of Rac and Rho may account for different biologic 
effects (Leeuwen et al., 1997; Sander et al., 1999). 
 Recent studies indicate that TIAM1 plays in an important role in the 
progression of epithelial cancers, especially carcinomas of the colon and breast 
(Minard et al., 2004; Morikawa et al., 1988a; Morikawa et al., 1988b). Colon 
cancer cell lines selected for a high migratory phenotype demonstrate increased 
TIAM1 expression levels and overexpression of TIAM1 in the parental cell line 
increases cell migration. Furthermore, both populations of cells demonstrate 
increased metastatic potential in the nude mouse (Minard et al., 2004). Another 
group reported that colon carcinoma cell lines selected for increased metastatic 
potential in the nude mouse expressed higher levels of TIAM1 than parental cell 
lines (Morikawa et al., 1988a; Morikawa et al., 1988b). Collectively, these data 
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indicate that TIAM1 may play a role in the progression and metastasis of colon 
cancer.  
 TIAM1 appears to play a similar role in promoting breast carcinoma 
progression. In murine breast cancer cells, the cellular adhesion molecule and 
receptor for hyaluronic acid (HA) binding receptor CD44 binds TIAM1, resulting in 
an increase in TIAM1-mediated Rac1 activation and cytoskeleton-mediated 
tumor cell migration (Bourguignon et al., 2000; Underhill et al., 1987). 
Furthermore, TIAM1 overexpression induces cellular ruffles and loss of 
intracellular adhesiveness, and increases the migratory and invasive phenotypes 
of breast cancer cell lines. In human breast carcinomas, a close correlation was 
observed between increased expression of TIAM1 and the invasiveness of 
breast tumor cells with the degree of progression of breast tumors (Adam et al., 
2001). In support of these findings, TIAM1 expression was reported to correlate 
with migratory capabilities and metastatic potential in a panel of eleven human 
breast cancer cell lines (Minard et al., 2004). These results suggest that 
increased TIAM1 activity or expression may promote breast cancer progression. 
However, expression of TIAM1 in breast carcinoma metastases remains to be 
determined. 
In breast carcinoma cells, TIAM1 overexpression is likely to constitutively 
activate the GTPases Rac, Rho, or Cdc42. Activation of these proteins in turn 
activates downstream signaling pathways capable of promoting cell migration 
and invasion, critical properties in the development of the metastatic phenotype. 
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Therefore, future studies elucidating the signaling pathways involving TIAM1 are 
needed to provide important insights into the progression and metastasis of 
breast carcinoma.  
 
FLT-1 
 Another important process in cancer progression and metastasis is 
angiogenesis, the development of new blood vessels. Blood vessel formation 
between a tumor and its surrounding tissue is essential for cancer growth, 
because it provides tumor cells with oxygen and other vital nutrients (Folkman, 
1992). Carcinoma cells themselves stimulate angiogenesis via production and 
secretion of vascular endothelial growth factor (VEGF) (Verheul and Pinedo, 
2000). VEGF interacts with vicinal endothelial cell receptors in a paracrine 
fashion, including FLT-1 (fms-related tyrosine kinase 1, aka VEGFR-1) and KDR 
(kinase insert domain receptor, aka VEGFR-2), as well as co-receptors 
neuropilin-1(NRP1) and neuropilin-2 (NRP2), to drive signaling pathways 
promoting formation of new blood vessels (Shibuya, 2001). VEGF is considered 
to be an essential factor in cancer progression, because of its positive effects on 
blood vessel formation (Zachary, 1998). However, recent work has shown that 
the VEGF receptors FLT-1, NRP1, and NRP2 are also present on the surface of 
some carcinoma cells, indicating that VEGF may affect tumor cells directly in an 
autocrine or paracrine manner as well. In fact, VEGF has been demonstrated to 
function in an autocrine manner in breast carcinoma cells to stimulate signaling 
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pathways that maintain cell survival (Bachelder et al., 2002). Furthermore, 
survival of colon carcinoma cells was found to be dependent on a FLT-1-
mediated VEGF autocrine signaling pathway (Bates et al., 2003). Such an 
elaboration of autocrine signaling pathways provides carcinoma cells with a 
degree of self-sufficiency that increases their probability to progress and possibly 
become invasive and/or metastatic.  
 The contribution of VEGF signaling in carcinoma cells to their ability to 
evade cell death is a significant advance in our understanding of the role of 
VEGF in cancer biology. Moreover, a novel result that derives from this finding is 
the involvement of FLT-1 in mediating VEGF survival signaling (Bates et al., 
2003). FLT-1 is one of two high affinity receptor tyrosine kinases for VEGF, the 
second being KDR. VEGF co-receptors NRP1 and NRP2 lack intrinsic signaling 
properties and are thought to function as co-receptors that enhance VEGF 
binding to FLT-1 and KDR.  FLT-1 demonstrates a higher binding affinity for 
VEGF in comparison with KDR, but weak tyrosine kinase activity (Waltenberger 
et al., 1994). FLT-1 was initially believed act as a decoy receptor, leading to 
negative regulation of VEGF signaling by preventing VEGF binding to KDR. 
Subsequent studies revealed that FLT-1 plays a critical role in the growth and 
migration of endothelial cells in both developmental and pathologic angiogenesis 
(Barleon et al., 1996; Hiratsuka et al., 2001) and that this activity is independent 
of the tyrosine kinase domain (Hiratsuka et al., 1998). FLT-1 was later identified 
as a key factor in promoting the migration of monocytes and macrophages, 
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inflammatory diseases, atherosclerosis, and cancer metastasis (Sawano et al., 
2001; Shibuya, 2006). Specifically, FLT-1 expression on bone marrow-derived 
cells promotes cancer metastases by promoting the infiltration of these cells and 
inducing matrix metalloproteinase-9 in premetastatic tissues, forming a 
“premetastatic niche” (Kaplan et al., 2005). Remarkably, inhibition of these FLT-1 
positive hematopoietic progenitors using an anti-FLT-1 peptide prevented 
formation of metastases (Bae et al., 2005).  
 FLT-1 acts as a receptor for placental growth factor (PlGF) in addition to 
VEGF. PlGF signals directly through FLT-1 in several cell types, including 
endothelial cells, macrophages, and tumor cells, thereby acting to promote tumor 
angiogenesis, tumor growth, and the formation of the premestastatic niche 
(Fischer et al., 2008). Emerging reports have documented that PlGF might be a 
prognostic marker for some tumor types, including breast. In fact, PlGF levels in 
breast cancer are reported to correlate with recurrence, metastasis, and mortality 
(Parr et al., 2005), and αPlGF therapy has been found to block tumor growth, 
metastasis, lymphangiogenesis, and angiogenesis (Fischer et al., 2007). 
Collectively, these findings suggest that FLT-1 signaling represents an important 
target in the suppression of cancer progression and metastasis. 
Recent studies indicate that FLT-1 expression is upregulated in several 
human carcinoma cell lines, as well as several common tumors, including 
prostate, breast and colon (Andre et al., 2000; Fan et al., 2005; Jackson et al., 
2002; Plate et al., 1994; Price et al., 2001; Speirs and Atkin, 1999). Furthermore, 
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expression of FLT-1 in various carcinoma cells has been found to correlate with 
cancer progression, cell survival (Bates et al., 2003), proliferation, migration and 
invasion (Fan et al., 2005; Lesslie et al., 2006; Wey et al., 2005), and distant 
metastasis (Hiratsuka et al., 2002). In pancreatic cancer, FLT-1 is reported to 
mediate EMT via increased activity of the transcription factors Snail, Twist, and 
Slug (Yang et al., 2006). A recent study in breast carcinoma suggests that FLT-1 
enhances cell survival through an internal autocrine signaling pathway (Lee et 
al., 2007). However, the regulation and function of FLT-1 in breast carcinoma 
remain largely unknown.  
Gene expression profiling of node-negative primary breast tumors 
revealed that FLT-1 expression is a key component of a ‘poor prognosis gene 
signature’ that is strongly predictive of a short interval to distant metastases (van 
't Veer et al., 2002). This finding is substantiated by the fact that FLT-1 
expression, as assessed by immunohistochemistry, correlates with a high risk of 
metastasis and relapse in both node negative and invasive breast cancer (Ghosh 
et al., 2008; Meunier-Carpentier et al., 2005; Mylona et al., 2007). Notably, anti-
FLT-1 antibody or FLT-1-specific inhibitory peptides suppress tumor growth and 
metastasis in various models, including breast (Bae et al., 2005; Luttun et al., 
2002; Taylor and Goldenberg, 2007; Wu et al., 2006). Collectively, these studies 
indicate that FLT-1 may promote an aggressive phenotype in human breast 
cancer, but further studies are necessary to ascertain its function and how it is 
regulated.  
17 
 
I hypothesize that miR-10b plays a key role in breast cancer progression, 
in part via the regulation of cell motility through TIAM1 and FLT-1. My thesis 
work, presented in the following chapters, explores the function of miR-10b in 
breast cancer, its ability to regulate putative targets TIAM1 and FLT-1 in breast 
cancer, and the function of FLT-1 in breast cancer.  
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Figure 1. MiRNA biogenesis.  
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews 
Cancer 6, 259-269 (April 2006). 
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Figure 2. Rho family GTPases and their regulators. 
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews 
Molecular Cell Biology 9, 846-859 (November 2008) 
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CHAPTER II 
 
MIR-10B IMPEDES BREAST CARCINOMA CELL MIGRATION and INVASION 
BY TARGETING TIAM1 
 
Introduction 
 MicroRNAs (miRNAs) are a class of small noncoding RNAs that control 
gene expression by targeting mRNAs and triggering either translational 
repression or mRNA degradation. Recent evidence has shown that miRNAs are 
aberrantly expressed in human cancer (Calin and Croce, 2006; Iorio et al., 2005; 
Lu et al., 2005; Ozen et al., 2008) and that they can affect key cell biological 
processes that affect tumor progression including migration, invasion, epithelial 
to mesenchymal transition (Burk et al., 2008; Korpal et al., 2008), and metastasis 
(Huang et al., 2008; Tavazoie et al., 2008; Zhu et al., 2008). The challenge 
ahead is to elucidate specific mechanisms by which miRNAs regulate such 
processes.  
 MiR-10b is one of 29 miRNAs whose expression has been reported to be 
significantly deregulated in breast cancer (Iorio et al., 2005). This miRNA 
achieved prominence because its expression in primary breast tumors was found 
to correlate with their ability to metastasize, and it was shown to promote the 
migration and invasion of breast carcinoma cells in vitro (Ma et al., 2007). 
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However, this seminal role for miR-10b in breast cancer was challenged recently 
based on the analysis of miR-10b expression in a large group of patients with 
early breast cancer (Gee et al., 2008). In this study, miR-10b expression did not 
correlate with development of distant metastases, recurrence-free survival or 
distant-relapse-free survival. Instead, miR-10b expression correlated inversely 
and significantly with tumor size, grade, and vascular invasion. These data infer 
that miR-10b impedes specific functions associated with breast cancer 
progression, and they highlight the need for more mechanistic studies.  
In this study, I present my analysis of miR-10b function in breast 
carcinoma cells, which revealed that it suppresses their migration and invasion.  
To define a mechanism that accounts for this suppressive function, I identified 
TIAM1, a GEF for Rac, as a miR-10b target and demonstrated that miR-10b 
inhibits TIAM1-dependent Rac activation, migration, and invasion. These data 
reveal a novel function of miRNAs and they support the conclusion from clinical 
data that miR-10b expression correlates inversely with breast cancer 
progression. 
 
Results 
To assess the ability of miR-10b to regulate migration and invasion as 
reported previously, I used two breast carcinoma cell lines (SUM-149PT and 
SUM-159PT) that are highly motile and invasive, and one (T47D) that is not 
(Dong et al., 2007; Flanagan et al., 1999; Gordon et al., 2003).  Reverse 
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transcriptase (RT)-PCR analysis revealed that SUM-149PT and SUM-159PT 
cells lack miR-10b expression but that T47D cells express miR-10b (Fig. 1A).  To 
examine whether exogenous expression of miR-10b influences migration, I used 
a miR-10b precursor for de novo expression in SUM-159PT cells. This precursor 
is a chemically-modified double-stranded RNA modeled on the sequence of 
mature miR-10b. For a control, I designed a miR-10b mutant with a single base 
pair substitution in the seed sequence of the mature strand (Fig. 1B). By 
introducing mismatch into the critical seed region, binding of the miRNA to its 
target genes should be reduced or abolished. A non-targeting miRNA was used 
as an additional negative control. Transient expression of miR-10b in SUM-
159PT cells resulted in expression of mature miR-10b, as assessed by RT-PCR 
(Fig. 1C). The miR-10b mutant, differing from miR-10b by a single base pair, is 
also detected by the primers used. To examine whether the miR-10b mutant was 
being expressed at the same level as miR-10b, I used quantitative RealTime 
PCR to amplify miR-10b and the miR-10b mutant using sequence specific 
primers and found that the miR-10b mutant was expressed 1.5-fold higher than 
miR-10b (Fig. 1C), allaying concerns that the miR-10b mutant was expressed at 
lower levels than miR-10b.  
For migration and invasion assays, transwells were coated with 15 µg/ml 
collagen or 0.5 µg matrigel, respectively. Cells expressing miR-10b, miR-10b 
mutant, or non-targeting control were then seeded into the upper chamber in 
serum-free medium and allowed to migrate/invade towards NIH-3T3-conditioned 
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medium for 4 hours at 37⁰C. Expression of miR-10b resulted in a 40% decrease 
in both migration and invasion as compared to non-targeting control miRNA (Fig. 
1D).  
To confirm that miR-10b, in contrast to published results, inhibits cell 
motility and that I was not observing an artifact of the miRNA precursor, I utilized 
a miR-10b expression vector. This retroviral vector encodes the genomic 
sequence of the human miR-10b gene in the 3’ UTR of green fluorescent protein 
(GFP) and requires that mature miR-10b be generated through endogenous 
cellular processing. I used this vector to express miR-10b in SUM-159PT cells 
and confirmed expression of the mature sequence by RT-PCR (Fig. 1E). Ectopic 
expression of this miR-10b resulted in greater than 50% decrease in both cell 
migration and invasion in comparison to the empty vector control (Fig. 1E). To 
further verify this result, miR-10b was expressed in SUM-149PT cells, which 
resulted in a 40% decrease in cell migration and invasion over a 16 hour period 
(Fig. 1F). In the previous publication by Ma et al. (2007), the same cell line 
transduced with the very same expression vector resulted in an increase in cell 
migration and invasion. My culture conditions for the SUM-149PT cells were 
identical to those published, but I discovered that my migration assays were 
conducted slightly differently. To account for these differences, I followed the 
published protocol of using non-coated transwells for migration assays, with 10% 
serum as the chemoattractant in the lower chamber. In striking contrast to 
24 
 
published results, cells expressing miR-10b exhibited a greater than 3-fold 
decrease in cell migration under these conditions (Fig. 1G).  
I next asked whether inhibition of endogenous miR-10b in T47D cells 
would affect their motility. For this purpose, I designed an antisense 
oligonucleotide to silence miR-10b. Indeed, expression of antisense miR-10b 
increased both migration and invasion of T47D cells by approximately 2-fold (Fig. 
2).  
To understand the mechanisms by which miR-10b represses cell motility, I 
used computational algorithms to identify miR-10b target genes. The search 
program TargetScan revealed several predicted targets known to play a role in 
cell migration and invasion, including T lymphoma invasion and metastasis 1 
(TIAM1) and nuclear factor of activated T cells 5 (NFAT5). TIAM1 was of 
particular interest because its expression correlates with epithelial tumorigenicity, 
the metastatic potential of human breast cancer cell lines (Minard et al., 2004), 
and increased breast cancer grade (Adam et al., 2001). The predicted target site 
for miR-10b is a single 8mer site, comprised of the seed match flanked by both 
the match at position 8 and the A at position 1 (Lewis et al., 2005). I observed a 
dramatic reduction in TIAM1 protein levels in both SUM-159PT and SUM-149PT 
cells expressing miR-10b, as compared to controls (Fig. 3A and 3B). Co-
transfection of the miR-10b precursor with miR-10b antisense rescued 
expression of TIAM1. Conversely, transfection of miR-10b antisense in T47D 
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cells to silence endogenous miR-10b led to a corresponding increase in TIAM1 
protein (Fig. 3C).   
To determine whether regulation of TIAM1 expression by miR-10b is 
direct, I utilized a luciferase reporter gene fused to the wild-type TIAM1 3’UTR. 
Expression of miR-10b reduced the activity of luciferase while a miR-10b seed 
mutant had no effect, indicating that miR-10b targets TIAM1 directly (Fig. 3D). As 
a control, I developed a second luciferase reporter with a single base pair 
mutation in the TIAM1 3’UTR, at the site corresponding to the miR-10b seed 
mutant. MiR-10b had no effect on the luciferase activity of this reporter, whereas 
the miR-10b seed mutant, a perfect match in the seed region, repressed the 
luciferase signal.  
Next, I asked whether TIAM1 downregulation is responsible for inhibition 
of cell motility by miR-10b. To determine whether SUM-159PT cells are 
dependent on TIAM1 for cell motility, I diminished TIAM1 expression in these 
cells using a TIAM1 siRNA pool (Fig. 4A). Knockdown of TIAM1 resulted in a 
40% decrease in both cell migration and cell invasion, similar to the change seen 
with de novo expression of miR-10b. Importantly, co-transfection of miR-10b and 
TIAM1 cDNA lacking the 3’UTR, and therefore the miR-10b target site, was able 
to rescue miR-10b-induced repression of cell motility (Fig. 4B). 
TIAM1 is a guanine nucleotide exchange factor for Rac, a Rho-GTPase 
that regulates actin dynamics at the leading edge during cell movement. I 
hypothesized that miR-10b-induced downregulation of TIAM1 results in a 
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corresponding decrease in Rac activation, thereby impairing cell motility. 
Decreasing TIAM1 expression in SUM-159PT cells by siRNA resulted in a 60% 
decrease in Rac1 activation (Fig. 5A). Similarly, de novo expression of miR-10b 
in this cell line also repressed activation of Rac1 (Fig. 5B). Co-transfection of 
miR-10b and TIAM1 cDNA restored Rac1 activation to control levels (Fig. 5C). 
 
Discussion 
MiR-10b has been reported to be downregulated in breast cancer, 
however, it has also been postulated to promote cell motility and increase 
metastatic capabilities (Iorio et al., 2005; Ma et al., 2007). Recent evidence 
suggests that miR-10b is, in fact, not correlated with distant metastases, instead 
exhibiting an inverse correlation with tumor size, grade and vascular invasion 
(Gee et al., 2008). These discrepancies clearly show the need for more 
mechanistic studies regarding miR-10b and breast cancer. In the present study, I 
examined the role of miR-10b in various human breast cancer cell lines. 
Specifically, I utilized miR-10b null SUM-159PT and SUM-149PT cells in addition 
to miR-10b-expressing T47D cells. An interesting observation is that T47D cells, 
a differentiated epithelial strain derived from a pleural effusion of infiltrating ductal 
carcinoma (Keydar et al., 1979), are relatively non-motile in vitro and non-
metastatic in vivo. SUM-159PT cells are an aggressive triple negative line (ER-
/PR-/Her2-) derived from anaplastic carcinoma. These miR-10b null cells display 
a stellate morphology characteristic of a metastatic phenotype and develop 
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secondary tumors following orthotopic injection in nude mice (Flanagan et al., 
1999). Similarly, SUM-149PT cells are derived from locally invasive inflammatory 
breast cancer, a particularly lethal form of breast cancer. These cells are 
postulated to undergo metastatic spread via a passive mechanism as tumor 
emboli, but are metastatic nonetheless (Hoffmeyer et al., 2005). This observation 
that miR-10b is expressed in an epithelial-like, non-metastatic cell line, but not in 
an invasive or aggressive metastatic cell line, is in direct contrast to previously 
published results that miR-10b is highly expressed only in metastatic breast 
cancer cells (Ma et al., 2007). 
 To assess miR-10b function in these cells, I first examined cell motility. 
Surprisingly, de novo expression of a miR-10b precursor in the highly motile 
SUM-159PT cells significantly repressed both cell migration and invasion, again 
in direct contrast to published results (Ma et al., 2007). A custom-designed miR-
10b mutant, possessing a single base mutation in the critical seed region of miR-
10b, showed little to no effect on cell motility, suggesting that the results obtained 
were specific to miR-10b. However, to ensure that I was not observing an artifact 
of the precursor miRNA, I went on to repeat these experiments using a retrovirus 
encoding the miR-10b gene, thereby allowing transcription and processing of 
miR-10b to occur endogenously. I was able to obtain the same retroviral plasmid 
used by Ma et al. (2007) for their experiments showing that miR-10b increases 
cell motility. Interestingly, I found that SUM-159PT cells transduced with the miR-
10b retrovirus showed a significant reduction in both cell migration and invasion 
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in comparison to virus encoding the empty vector. These results support my 
earlier data obtained with the miR-10b precursor. However, to ensure that I was 
not observing a cell-type specific phenomenon, I transduced SUM-149PT cells, 
the same cells used by Ma et al. (2007), with the miR-10b retrovirus. These cells 
also demonstrated a significant decrease in both cell migration and invasion in 
comparison to empty vector controls. Unable to explain the striking discrepancy 
between my findings and the literature, I repeated the SUM-149PT cell assays 
under experimental conditions identical to the published protocol (Ma et al., 
2007). My cell culture conditions were the same, and the cells themselves had 
been obtained from the same source. I modified my own protocol for the 
migration assays to use uncoated transwells for assessing migration towards 
media containing 10% serum over a 24 hour period and found that miR-10b 
again repressed cell migration. While I cannot rule out the possibility of acquired 
cell differences, the results obtained clearly indicate that miR-10b suppresses 
cell migration and invasion in breast carcinoma cells.  
 I was interested to conduct the reverse experiment and determine if 
inhibition of endogenous miR-10b would increase cell motility. For these 
experiments I utilized the relatively immotile, miR-10b-positive T47D cells and 
observed a striking increase in both cell migration and invasion in cells 
expressing miR-10b antisense. These results further indicate that miR-10b 
suppresses breast carcinoma cell migration and invasion, and refute published 
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data that miR-10b promotes breast cancer invasion and metastasis (Ma et al., 
2007). 
 Review of putative miR-10b targets known to play a role in cell motility led 
us to TIAM1, a cytoplasmic protein that was originally identified through 
propagation of invasive cells (Habets et al., 1994). The results obtained show 
that TIAM1 protein levels are repressed by expression of miR-10b, and 
enhanced by inhibition of endogenous miR-10b. Luciferase assays confirmed 
that regulation of TIAM1 by miR-10b occurs via direct interaction at the TIAM1 
3’UTR. The finding that miR-10b regulates TIAM1, a GEF for Rac, is a novel and 
exciting discovery. Further investigation showed that expression of a TIAM1 
cDNA lacking the 3’UTR, and therefore immune to the effects of miR-10b, 
restored cell migration, suggesting that TIAM1 is the primary factor responsible 
for decreased cell motility in cells expressing miR-10b. 
 Rac1 functions downstream of TIAM1 to promote cytoskeletal 
rearrangement during cell migration (Ehler et al., 1997; Michiels et al., 1995; 
Stam et al., 1997) and my results confirm that TIAM1 expression is necessary for 
optimal Rac1 activation in breast carcinoma cells and identify an elegant 
mechanism in which miR-10b downregulates TIAM1 leading to decreased 
activation of Rac1 and a decrease in cell motility.  
An important conclusion drawn from my data is that TIAM1-mediated 
Rac1 activation, migration, and invasion can be regulated by a specific miRNA.  
Although it is known that TIAM1 expression increases with breast cancer grade, 
30 
 
little is known about how this GEF is regulated in breast tumors. The ability of 
miR-10b to target TIAM1 provides one such mechanism, which is substantiated 
by the recent observation that miR-10b expression decreases as a function of 
grade in breast cancer (Gee et al., 2008).  
My data contrast markedly with the data reported by Ma et al. (2007), who 
concluded that miR-10b promotes the migration and invasion of breast 
carcinoma cells by a mechanism that involves the HoxD10 induction of RhoC 
expression. Given that I used the same cell lines (e.g., SUM-149PT) and 
experimental conditions, it is difficult to reconcile this opposing conclusion of 
miR-10b function in breast cancer.   My mechanistic data, however, support the 
recent observation that miR-10b expression in human breast tumors correlates 
inversely with a more invasive phenotype as indicated by tumor stage, grade and 
vascular invasion (Gee et al., 2008).  I also question the purported role of miR-
10b in inducing RhoC expression because our laboratory had reported previously 
that SUM-149PT cells, which were shown to lack miR-10b expression by both 
myself (Fig. 1) and Ma et al. (2007), express relatively high levels of RhoC 
(Simpson et al., 2004). 
 
Materials and Methods 
Cell lines: The SUM-159PT and SUM-149PT cell lines were obtained from Dr. 
Steve Ethier (University of Michigan) and cultured in HamsF12 supplemented 
with 5% fetal bovine serum, insulin (5 µg/ml, Sigma), hydrocortisone (1 µg/ml, 
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Sigma), and  1% penicillin-streptomycin. T47D and 293T cells were obtained 
from ATCC (American Type Culture Collection, Rockville, MD, USA). T47D cells 
were cultured in RPMI-1640 supplemented with 10% fetal bovine serum, 0.2 
Units/ml bovine insulin, and 1% penicillin-streptomycin. 293T cells were cultured 
in low glucose DMEM supplemented with 10% fetal bovine serum and 1% 
penicillin-streptomycin.  
RNA isolation and miRNA detection: Total RNA was isolated from cultured 
cells using the mirVana miRNA Isolation Kit (Ambion). Detection of the mature 
form of miRNAs was performed using the mirVana qRT-PCR miRNA Detection 
Kit and qRT-PCR Primer Sets, according to the manufacturer’s protocols 
(Ambion). For qPCR, detection of the mature form of miRNAs was performed 
using TaqMan miRNA Reverse Transcription Kit and TaqMan Human Microarray 
Assays for miR-10b and miR-10b mutant (Ambion). U6 small nuclear RNA was 
used as an internal control. 
Oligonucleotide transfection: Pre-miR miRNA Precursor Molecules (Ambion) 
are synthetic miRNA mimics designed for functional analyses and target site 
validation. Cells were transfected at 50% confluence with 20 nM of the following 
miRNA precursors using DharmaFECT 4 transfection reagent (Dharmacon): Pre-
miR hsa-miR-10b Precursor, a custom-designed miR-10b seed mutant precursor 
with a single base pair substitution in the seed region of the mature strand, or a 
Pre-miR miRNA Precursor non-targeting Negative Control (Ambion). Seventy-
two hours after transfection, cells were plated for migration and invasion assays, 
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or harvested for Rac activity assays. A custom designed 2’-O-methyl antisense 
oligonucleotide (Dharmacon) directed against mature miR-10b was used for loss-
of-function analyses. Antisense oligonucleotides directed against luciferase were 
used for control. T47D cells were transfected with 20 nM of the antisense oligos 
as above. Nontargeting siRNA or siRNAs designed to target TIAM1 were SMART 
Pools from Dharmacon and cells were transfected with 20 nM of each pool. For 
TIAM1 rescue experiments, cells were transfected with 20-40 nM miRNA 
precursor and 0.6 pmol of a full length human TIAM1 full-length cDNA (Kathleen 
O’Connor, University of Texas) or empty vector control using DharmaFECT Duo 
transfection reagent (Dharmacon). 
Migration and invasion assays: For migration assays, both the upper and 
lower surfaces of transwell chambers (8-µm pore, Costar) were coated overnight 
with collagen (15 µg/ml, Becton Dickinson) diluted in PBS. For invasion assays, 
the upper surface of the transwells was coated overnight with 0.5 µg Matrigel 
(Becton Dickinson). Cells were harvested at 80% confluence by trypsinization 
and resuspended in HamsF12 or RPMI-1640 containing 0.25% heat inactivated 
fatty acid-free BSA. The coated surfaces of the transwells were blocked with 
media containing 0.25% BSA for 30-60 minutes at 37oC. Cells (2 x 104 in a total 
volume of 100 µl) were loaded into the upper chamber and NIH-3T3-conditioned 
media or media containing 10% serum was added to the lower chamber. Assays 
proceeded for 4 hours for SUM-159PT cells, and 24 hours for SUM-149PT and 
T47D cells at 37oC. Upon completion of the assay, the upper chamber was 
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swabbed to remove residual cells and fixed with methanol. Cells on the lower 
surface of the membrane were mounted in DAPI mounting media (Vector 
Laboratories) and the number of cells was determined for five independent fields 
with a 20X objective and fluorescence. Each experiment was performed in 
triplicate. 
Constructs: The MDH1-PGK-GFP-premiR-10b and MDH1-PGK-GFP vectors 
were obtained from Addgene. 293T cells were transfected at 50% confluence by 
a Lipofectamine (Invitrogen) complex containing envelope plasmid (1.75 µg), 
packaging plasmid (3.25 µg), and MDH1-PGK-GFP-2.0 vector expressing pre-
miR-10b or no insert in Optimem (Gibco). Two days following transfection the 
virus was harvested, clarified, and the supernatant was filtered through a 0.22-
µm filter to be used immediately or stored at -80oC. Recipient SUM-159PT and 
SUM-149PT cells were plated to reach 50% confluence after 24 hours, and virus 
was added to cells at a ratio of virus: fresh media containing Polybrene (8 µg/ml) 
of 1:1 and 1:2. For luciferase assay, a 60 bp region of the TIAM1 3’UTR 
containing the binding site for miR-10b was cloned into the pMIR-REPORT 
luciferase construct (Ambion). A second insert containing a single base pair 
mutation in the seed binding site, comparable to the miR-10b mutant, was cloned 
into the same construct to generate a luciferase construct with a mutated miR-
10b binding site for control. 
Immunoblotting: Whole cell lysates were prepared by lysis in ice-cold RIPA 
buffer [50 mM Tris (pH 8.0), 150 mM NaCl, 10 mM EDTA, 1% NP-40, 1% 
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deoxycholate, 0.1% SDS, 2 mM phenylmethylsulfonyl fluoride (PMSF), and 5 
µg/ml aprotinin, leupeptin, and pepstatin]. Lysates (50 µg) were separated by 
electrophoresis through 8 or 12% SDS-PAGE and transferred to 0.2 µm 
Nitrocellulose membrane (Bio-Rad Laboratories). Membranes were blocked in 
5% non-fat milk in TBS/Tween-20, blotted with the antibodies for TIAM1 (1:800, 
Santa Cruz), actin (1:5000, Sigma), or Rac1 (1:1000, Transduction Laboratories) 
overnight, followed by secondary peroxidase-conjugated anti-rabbit or anti-
mouse antibodies, and detection was by enhanced chemiluminescence.  
Luciferase Reporter Assay: Cells in 24-well plates at 50% confluence were co-
transfected with a firefly luciferase reporter gene construct (200 ng – 0.5 µg) and 
1 ng – 0.5 µg of Renilla-Luciferase construct (for normalization) using 
DharmaFECT Duo (Dharmacon). Cell extracts were prepared 24-48 hours after 
transfection and luciferase activity was measured using the Dual-Glo Luciferase 
Assay System (Promega).  
Rac Activity Assays: Rac activity assays were based on established protocols 
(Benard et al., 1999; Sander et al., 1998a). The bacterially produced Rac/Cdc42 
binding domain of Pak (PBD)-GST fusion protein was extracted and used to coat 
glutathione Sepharose beads (GE Healthcare). Serum starved cells were 
harvested by addition of ice-cold lysis buffer [50 mM Tris (pH 7.4), 100 mM NaCl, 
1% NP-40, 10% glycerol, 2 mM MgCl2, 2 mM PMSF, and 5 µg/ml each of 
aprotinin, leupeptin, and pepstatin]. Lysates were cleared by centrifugation and 
0.1 total volume was removed to represent the total lysate control. GST-PBD-
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coupled beads were added to the remaining lysates with 2 volumes of binding 
buffer [25 mM Tris (pH 7.5), 1 mM dithiothreitol, 40 mM NaCl, 30 mM MgCl2, 
0.5% Nonidet P-40] for 30 minutes on a rotating platform at 4oC. Beads were 
washed three times in binding buffer and eluted in 2X Laemmli sample buffer. 
Aliquots of both total cell extracts and the eluents from the PBD beads were 
immunoblotted for Rac1. 
Statistical analysis: Data are presented as the mean ± standard error of mean 
(SEM). The Student t-test was used to assess the significance of independent 
experiments. The criterion p < 0.05 was used to determine statistical significance. 
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Figure 1. MiR-10b suppresses breast carcinoma cell migration and 
invasion. A, RT-PCR of miR-10b in three different human breast cancer cell 
lines. B, Schematic showing the sequences of mature miR-10b and miR-10b 
seed mutant. The seed sequence of mature miR-10b is underlined. C, Upper 
panel, RT-PCR of miR-10b in SUM-159PT cells transfected with either non-
targeting control miRNA, miR-10b mutant, or miR-10b precursor. Lower panel, 
quantitative Real-Time PCR of miR-10b and miR-10b mutant in SUM-159PT 
cells transfected with either non-targeting control miRNA, miR-10b mutant, or 
miR-10b precursor. Each primer set is capable of amplifying both miR-10b and 
miR-10b mutant, with higher fidelity for the exact sequence and lower fidelity for 
the non-identical sequence. D, Migration and Matrigel invasion assays of the 
transfected SUM-159PT cells. *, P < 0.01. E, Upper panel, RT-PCR of miR-10b 
in SUM-159PT cells infected with miR-10b-expressing or empty vector retrovirus. 
Lower panel, migration and Matrigel invasion assays of infected SUM-159PT 
cells. *, P < 0.001. F, Migration and Matrigel invasion assays of SUM-149PT cells 
infected with miR-10b-expressing or empty vector retrovirus. *, P < 0.05. G, 
Migration assay of infected SUM-149PT cells migrating towards 10% serum 
through uncoated transwells. *, P < 0.001. Data for migration and invasion 
assays represent means ± SEM from 3 independent experiments.  
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Figure 2. Inhibition of endogenous miR-10b increases T47D cell migration 
and invasion. Migration and Matrigel invasion assays of T47D cells transfected 
with miR-10b antisense oligonucleotides. Antisense oligonucleotides directed 
against luciferase were used for negative control. *, P < 0.05. **, P < 0.005. Data 
represent means ± SEM from 3 independent experiments.  
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Figure 3. MiR-10b regulates expression of TIAM1. A, B, Immunoblot of TIAM1 
expression in SUM-159PT (A) and SUM-149PT (B) cells transfected with either 
non-targeting control miRNA, miR-10b mutant, miR-10b precursor, or co-
transfected with miR-10b precursor plus antisense miR-10b. C, Immunoblot of 
TIAM1 expression in T47D cells transfected with antisense oligonucleotides 
directed against luciferase (control) or miR-10b. The numbers under the blots 
represent densitometric analysis of the intensity of the TIAM1 bands relative to 
actin. D, Luciferase activity of a TIAM1 3’UTR or TIAM1 mutant 3’UTR reporter 
gene in SUM-159PT cells transfected with either miR-10b, miR-10b mutant, or 
non-targeting control miRNA. *, P < 0.05. **, P < 0.005. Data represent means ± 
SEM from 3 independent experiments. 
40 
 
 
Figure 4. Exogenous expression of TIAM1 rescues cell migration. A, 
Immunoblot of TIAM1 expression (upper panel) and migration and Matrigel 
invasion assays (lower panel) of SUM-159PT cells transfected with either a 
TIAM1 siRNA pool or a control siRNA pool. *, P < 0.01. **, P < 0.001. Data for 
migration and invasion assays represent means ± SEM from 3 independent 
experiments. B, Immunoblot (upper panel) and migration assay (lower panel) of 
SUM-159PT cells co-transfected with miR-10b or non-targeting control miRNA, 
and either a TIAM1 cDNA lacking the 3’UTR or empty vector. *, P < 0.001.  
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Figure 5. MiR-10b represses TIAM1-dependent activation of RAC1. SUM-
159PT cells were transfected with either a TIAM1 siRNA pool or a control siRNA 
pool (A), with either non-targeting control miRNA, miR-10b mutant, or miR-10b 
precursor (B), or with non-targeting control miRNA or miR-10b precursor co-
transfected with a TIAM1 cDNA lacking the 3’UTR or empty vector (C).  Cell 
extracts were analyzed for Rac1 activation using the PBD assay as described in 
Materials and Methods.  The numbers under the blots represent densitometric 
analysis of the intensity of the Rac1 bands.  
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CHAPTER III 
 
VEGF RECEPTOR FLT-1 REGULATION BY miR-10b CONTRIBUTES TO 
BREAST CANCER CELL MOTILITY 
 
Introduction 
VEGF produced locally by either tumor or stromal cells, in addition to its 
role in angiogenesis, engages VEGF receptors on tumor cells and initiates a 
signaling response that facilitates survival (Bachelder et al., 2002; Bates et al., 
2003; Das et al., 2005; Fragoso et al., 2006; Lee et al., 2007; Lipscomb et al., 
2005; Weigand et al., 2005). The VEGF/PlGF receptor FLT-1 is upregulated in 
many common tumors, including breast, and has been found to mediate VEGF 
autocrine signaling loops essential for survival in colon carcinoma cells (Bates et 
al., 2003) and in neuroblastoma cells exposed to hypoxia (Das et al., 2005). In 
breast carcinoma, FLT-1 has been identified as a key component of a ‘poor 
prognosis gene signature’ that is strongly predictive of a short interval to distant 
metastases (van 't Veer et al., 2002) and FLT-1 expression in primary tumors has 
been correlated with a high risk of metastasis and relapse (Ghosh et al., 2008; 
Meunier-Carpentier et al., 2005; Mylona et al., 2007). Furthermore, anti-FLT-1 
antibody or FLT-1 specific inhibitory peptides are reported to suppress tumor 
growth and metastasis in various tumor models, including breast (Bae et al., 
43 
 
2005; Taylor and Goldenberg, 2007; Wu et al., 2006). Based on these findings, I 
hypothesize that FLT-1 may contribute to the migration and invasion of breast 
tumor cells, thereby promoting an aggressive phenotype. 
MiR-10b is one of 5 miRNAs whose expression has been reported to be 
significantly downregulated in breast cancer (Iorio et al., 2005). Furthermore, 
miR-10b expression correlated inversely and significantly with tumor size, grade 
and vascular invasion in a cohort of patients with early breast cancer (Gee et al., 
2008). These data infer that miR-10b impedes specific functions associated with 
breast cancer progression. In support of this notion, I have shown that miR-10b 
suppresses migration and invasion of breast carcinoma cells via downregulation 
of GEF TIAM1 and inhibition of TIAM1 dependent Rac activation (Chapter 2). 
Interestingly, FLT-1 is also a putative target of miR-10b, but the function of FLT-1 
in breast cancer remains largely unknown.  
In this study, I present my analysis of FLT-1 function in breast carcinoma 
cells, which revealed that it is a valid target of miR-10b and that it functions to 
suppress both cell migration and invasion. 
 
Results  
To assess the ability of miR-10b to regulate FLT-1 expression in breast 
cancer, I used a miR-10b precursor for de novo expression in a miR-10b-null, 
highly invasive breast carcinoma cell line, SUM-159PT (Flanagan et al., 1999; 
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Ma et al., 2007). Transient expression of miR-10b in SUM-159PT cells resulted in 
expression of mature miR-10b, as assessed by RT-PCR (Fig. 1A). I observed a 
dramatic downregulation of FLT-1 protein levels in cells expressing miR-10b as 
compared to non-targeting control miRNA (Fig. 1B).  
The search program Targetscan revealed that VEGF co-receptor 
neuropilin 2 (NRP2) is also a putative target of miR-10b. NRP2 has recently been 
implicated as a positive factor in cancer metastasis (Caunt et al., 2008). To 
assess the validity of this target, miR-10b was expressed in MDA-MB-435 cells, 
which express both endogenous miR-10b and NRP2. Transient overexpression 
of miR-10b caused a significant suppression of FLT-1 protein expression, but did 
not suppress NRP2 as compared to non-targeting control miRNA (Fig. 1C).  
Since both de novo expression and overexpression of miR-10b 
suppressed expression of FLT-1, I next asked whether inhibition of endogenous 
miR-10b would increase FLT-1 expression. For this purpose, I expressed a miR-
10b antisense oligonucleotide or control antisense directed against luciferase in 
miR-10b-positive T47D breast cancer cells. Immunoblot analysis revealed a 
significant increase of FLT-1 protein in cells expressing miR-10b antisense (Fig. 
1D). 
FLT-1 expression in breast cancer has been previously correlated with 
poor prognosis and a high risk of metastasis and relapse, but its function is 
poorly understood. To examine the function of FLT-1 in breast cancer, I turned to 
FLT-1 RNAi to suppress FLT-1 expression for loss-of-function studies. I found 
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that FLT-1 was very difficult to knockdown in breast cancer cell lines. 
Commercially available siRNA pools, shRNA viral vectors, and published siRNA 
sequences reported to knockdown FLT-1 in endothelial cells (Kou et al., 2005) all 
failed to repress FLT-1 expression in my hands (data not shown). Therefore, I 
designed a unique siRNA to the FLT-1 3’UTR, proximal to the miR-10b target 
site. This siRNA successfully and significantly repressed expression of FLT-1 in 
SUM-159PT cells (Fig. 2A).  
 Since I have previously shown that miR-10b suppresses breast cancer 
cell motility, and FLT-1 is extensively implicated in breast cancer progression, I 
hypothesized that FLT-1 contributes to cell migration and invasion in breast 
cancer. To determine the best chemoattractant for cell motility assays, serum-
starved cells were placed in the upper chamber of transwells coated with 15 
µg/ml collagen and allowed to migrate towards serum-free medium (SFM), NIH-
3T3 conditioned medium, or physiologic concentrations of PlGF, VEGF, or VEGF 
plus heparin. I observed robust migration towards NIH-3T3-conditioned medium, 
however, the cells did not exhibit enhanced migration towards either PlGF or 
VEGF in comparison to SFM (Fig. 2B, 2C).  Following transfection with FLT-1 
siRNA, cells were seeded into the upper chamber of transwells coated with 15 
µg/ml collagen and 0.5 µg matrigel to assess the role of FLT-1 in migration and 
invasion, respectively, toward NIH-3T3-conditioned medium. Knockdown of FLT-
1 resulted in approximately 30% reduction in cell migration and greater than 50% 
reduction in cell invasion (Fig. 2D).  
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 FLT-1 is receptor tyrosine kinase for VEGF and has been reported to 
promote cancer metastasis via its kinase activity (Shibuya, 2006). Furthermore, 
SUM-159PT cells engage in VEGF autocrine survival signaling (Lipscomb et al., 
2005). Therefore, I next examined FLT-1 auto-phosphorylation. Cells were 
serum-starved and treated with or without VEGF or serum. Auto-phosphorylation 
was assessed by FLT-1 immunoprecipitation followed by phosphotyrosine 
immunoblot. I did not observe phosphorylation of FLT-1 under any of the 
conditions tested (data not shown).  
 Since I failed to detect tyrosine phosphorylation of FLT-1, I next asked 
whether FLT-1 might be mutated in breast cancer, and specifically in the SUM-
159PT cells. A single amino acid substitution in the activation loop was recently 
reported to define the decoy characteristic of FLT-1 in endothelial cells (Meyer et 
al., 2006). To examine the sequence of FLT-1 in SUM-159PT cells for a similar 
mutation, I isolated genomic DNA from this cell line and sequenced all 30 exons 
of the FLT-1 gene using Transgenomic Surveyor/WAVE sequencing technology. 
Heterozygous analysis by denaturing HPLC revealed a C-T single-nucleotide 
polymorphism in the intron region preceeding exon 13 (nucleotides 1908-2004) 
(Fig. 3). Homozygous analysis comparing FLT-1 in SUM-159PT breast cancer 
cells to wild-type FLT-1 from human blood showed identical sequences with no 
mutations present. 
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Discussion  
Extensive studies in patient populations have identified FLT-1 as a key 
factor in poor prognosis breast cancer (Meunier-Carpentier et al., 2005; van 't 
Veer et al., 2002). Specifically, increased expression of FLT-1 in primary breast 
cancer correlates with a high risk of metastasis and relapse (Ghosh et al., 2008; 
Meunier-Carpentier et al., 2005; Mylona et al., 2007). Furthermore, treatment 
with anti-FLT-1 antibody or FLT-1 inhibitory peptides suppresses breast cancer 
growth and metastasis (Bae et al., 2005; Luttun et al., 2002; Taylor and 
Goldenberg, 2007; Wu et al., 2006). However, only one study to date has 
examined FLT-1 function in breast cancer, reporting that FLT-1 is involved in an 
internal autocrine survival signaling pathway (Lee et al., 2007). Based on these 
findings, FLT-1 plays a key role in breast cancer progression, but further study is 
necessary to examine FLT-1 function as a potential therapeutic target.  
I have previously identified miR-10b as a suppressor of cell motility in 
breast cancer via TIAM1-mediated Rac1 activation. Interestingly, FLT-1 is a 
potential target of miR-10b as well, identified by another group via TargetScan 
following the finding that miR-10b is significantly downregulated in breast cancer 
(Iorio et al., 2005). I hypothesized that FLT-1 is regulated by miR-10b and 
contributes to breast cancer cell motility. In the present study, I show that FLT-1 
is downregulated following de novo expression of miR-10b in breast cancer cells, 
indicating that FLT-1 is, in fact, a target of miR-10b. Interestingly, during the 
course of this work the sequence of FLT-1 was annotated in the NCBI database, 
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eliminating the miR-10b target site from the 3’UTR. As a result, TargetScan no 
longer identifies FLT-1 as a target of miR-10b. Another commonly used computer 
algorithm, PicTar, does identify FLT-1 as a putative miR-10b target. The current 
predictions by TargetScan and PicTar have a high degree of overlap because 
they both require stringent seed pairing between a miRNA and its target mRNA. 
However, differences may arise due to alignment artifacts, the use of different 
UTR databases, the use of different miRNA sequences, or the different prediction 
algorithms themselves (Bartel, 2009).  
Another putative target of miR-10b that is reported to play a role in cancer 
metastasis is VEGF co-receptor NRP2 (Caunt et al., 2008). SUM-159PT cells do 
not express NRP2, so I assessed the validity of this target in MDA-MB-435 cells. 
Although these cells express endogenous miR-10b, I found that transient 
overexpression of miR-10b caused significant downregulation of FLT-1 protein, 
but did not decrease NRP2 protein levels, suggesting that NRP2 may not be a 
valid target of miR-10b. In fact, TargetScan no longer identifies NRP2 as a miR-
10b target either. Similar to FLT-1, NRP2 is predicted to be a miR-10b target by 
PicTar, indicating that these predictions are subject to error and that 
experimental validation of miRNA targets is critical. 
I next examined whether inhibition of endogenous miR-10b increases 
FLT-1 protein expression. Inhibition of endogenous miR-10b in miR-10b-positive 
T47D cells would be expected to increase expression of FLT-1 protein by 
releasing miR-10b-induced downregulation. Indeed, I observed a significant 
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increase in FLT-1 protein by immunoblot, further indicating FLT-1 is a target of 
miR-10b in breast cancer.  
A recent study suggests that FLT-1 acts as part of an internal autocrine 
VEGF signaling pathway in breast cancer, thereby facilitating cell survival (Lee et 
al., 2007). To further examine the function of FLT-1 in breast cancer cells, I 
turned to RNAi. FLT-1 expression was easily suppressed by both expression and 
overexpression of miR-10b in our models. However, numerous FLT-1 siRNAs 
failed to knockdown FLT-1 expression. MiRNA sites in the mRNA 3'UTR, which 
interact with miRNA-loaded RNA-induced silencing complex (miRISC) for 
posttranscriptional gene regulation, provide alternative potentially accessible 
sites for siRNA (Wu et al., 2008). Given the success of miR-10b in suppressing 
FLT-1 via the 3’UTR, I designed a unique siRNA to the 3’UTR in close proximity 
to the miR-10b target site. Our siRNA is not predicted to target any other known 
mRNAs by BLAST. A recent publication investigated "difficult-to-silence" target 
mRNAs for which no functionally validated siRNAs are available, finding that 
siRNAs directed against the 3’UTR generally caused higher knockdown than 
previously designed siRNAs for these targets. In general, knockdown by siRNAs 
targeting the miRNA seed region was specific for the target mRNA, and siRNAs 
targeting 1 nt upstream of miRNA seed region were similarly potent (Bergauer et 
al., 2009). These findings indicate that siRNA to the 3’UTR is a valid and 
successful approach for “difficult-to-silence” target mRNAs such as FLT-1. 
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For FLT-1 loss-of-function studies I first looked to cell motility. I have 
previously shown that miR-10b suppresses breast cancer cell migration and 
invasion, and I hypothesized that FLT-1 may be contributing to this process. FLT-
1 has been shown to promote the migration of monocytes and macrophages, as 
well as migration and invasion of pancreatic and colon cancer cells (Fan et al., 
2005; Lesslie et al., 2006; Wey et al., 2005), suggesting that FLT-1 may play a 
universal role in cell motility. In fact, I observed a 0.5-fold and greater than 2-fold 
decrease in breast carcinoma cell migration and invasion, respectively, 
suggesting that FLT-1 promotes cell migration and, to a greater extent, invasion 
in breast cancer.  
To begin to examine the mechanism by which FLT-1 promotes breast 
cancer cell motility, I assessed FLT-1 auto-phosphorylation. FLT-1 promotes 
cancer metastasis via its kinase activity (Shibuya, 2006). I hypothesized that an 
increase in FLT-1 auto-phosphorylation activates downstream pathways which 
promote cell migration and invasion. Surprisingly, I found no evidence of FLT-1 
tyrosine auto-phosphorylation. Since PlGF and VEGF stimulation failed to induce 
chemotaxis or tyrosine phosphorylation, it is possible that the internal autocrine 
signaling pathway previously identified (Lee et al., 2007) may account for ligand-
independent migration in these cells. Additionally, expression of FLT-1 may 
promote a basal level of signaling (perhaps by an autocrine mechanism) that 
contributes to cell motility. Further investigation to examine the localization of 
FLT-1 in these cells is warranted. 
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Given the failure of previously validated siRNAs and the lack of tyrosine 
auto-phosphorylation in breast cancer, I asked whether FLT-1 is mutated in 
breast cancer. A mutation in the FLT-1 coding sequence has the potential to not 
only disrupt siRNA binding, but also to significantly alter protein function. 
Interestingly, a single amino acid substitution in the activation loop of FLT-1 has 
been reported to define the decoy characteristic of FLT-1 in endothelial cells 
(Meyer et al., 2006). I hypothesized that FLT-1 might have a similar mutation in 
breast cancer. However, extensive sequencing analysis revealed that FLT-1 has 
no mutations in the SUM-159PT breast cancer cell line. Homozygous analysis 
comparing FLT-1 in breast cancer to wild-type FLT-1 in human blood showed no 
differences, while heterozygous analysis of the two FLT-1 alleles in SUM-159PT 
cells showed only a single nucleotide polymorphism located in an intron region 
and therefore likely to be silent. Collectively, these results suggest that FLT-1 is 
not mutated in SUM-159PT breast cancer cells.  
My data show, for the first time, that the VEGF receptor FLT-1 can be 
regulated by a specific miRNA. Although it is known that FLT-1 expression 
correlates with a poor prognosis in breast cancer, little is known about its function 
or how it is regulated in breast tumors. The ability of miR-10b to target FLT-1 
provides one mechanism for regulation of FLT-1 expression, which is 
substantiated by the recent finding that miR-10b expression decreases as a 
function of breast cancer grade (Gee et al., 2008). 
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Importantly, I have identified a novel function for FLT-1 in promoting 
breast cancer cell migration and invasion. These data are in agreement with 
previous findings that FLT-1 expression correlates with a high risk of metastasis 
and that inhibition of FLT-1 by anti-FLT-1 antibody or specific inhibitory peptides 
suppresses breast cancer growth and metastasis (Bae et al., 2005; Taylor and 
Goldenberg, 2007; Wu et al., 2006). Although further studies are necessary to 
examine the downstream pathways of FLT-1 in breast cancer cell motility, these 
data provide evidence that FLT-1 plays a key role in promoting breast cancer. 
 
Materials and Methods 
Cell lines: The SUM159PT cell line was obtained from Dr. Steve Ethier 
(University of Michigan) and cultured in HamsF12 supplemented with 5% fetal 
bovine serum, insulin (5 µg/ml, Sigma), hydrocortisone (1 µg/ml, Sigma), and  1% 
penicillin-streptomycin. MDA-MB-435 and T47D cell lines were obtained from 
ATCC (American Type Culture Collection, Rockville, MD, USA). MDA-MB-435 
cells were cultured in low glucose DMEM supplemented with 10% fetal bovine 
serum and 1% penicillin-streptomycin. T47D cells were cultured in RPMI-1640 
supplemented with 10% fetal bovine serum, 0.2 Units/ml bovine insulin, and 1% 
penicillin-streptomycin.  
RNA isolation and miRNA detection: Total RNA was isolated from cultured 
cells using the mirVana miRNA Isolation Kit (Ambion). Detection of the mature 
form of miRNAs was performed using the mirVana qRT-PCR miRNA Detection 
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Kit and qRT-PCR Primer Sets, according to the manufacturer’s protocols 
(Ambion). U6 small nuclear RNA was used as an internal control. 
Oligonucleotide transfection: Pre-miR miRNA Precursor Molecules (Ambion) 
are synthetic miRNA mimics designed for functional analyses and target site 
validation. Cells were transfected at 50% confluence with 20 nM of Pre-miR hsa-
miR-10b Precursor or a Pre-miR miRNA Precursor non-targeting Negative 
Control using DharmaFECT 4 transfection reagent (Dharmacon). Seventy-two 
hours after transfection, cells were plated for migration and invasion assays. A 
locked nucleic acid miR-10b antisense oligonucleotide and 2’-O-methyl antisense 
oligonucleotide (Dharmacon) targeting mature miR-10b were used for loss-of-
function analyses. Antisense oligonucleotides targeting luciferase were used for 
negative control. T47D cells were transfected with 20 nM of antisense oligo as 
above. FLT-1 siRNA was designed to target the FLT-1 3’UTR (Sense strand: 5’-
GCCUACUCUUCAGGGUCUAGC-3’, Antisense strand: 5’-
UAGACCUGAAGAGUAGGCGC-3’). Control siRNA is a non-targeting negative 
control siRNA (Ambion). Cells were transfected with 20 nM of each siRNA.  
Migration and invasion assays: For migration assays, both the upper and 
lower surfaces of transwell chambers (8-µm pore, Costar) were coated overnight 
with collagen (15 µg/ml, Becton Dickinson) diluted in PBS. For invasion assay, 
the upper surface of the transwells were coated overnight with 0.5 µg Matrigel 
(Becton Dickinson). Cells were harvested at 80% confluence by trypsinization 
and resuspended in HamsF12 containing 0.25% heat inactivated fatty acid-free 
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BSA. The coated surfaces of the transwells were blocked with media containing 
0.25% BSA for 30-60 minutes at 37oC. Cells (2 x 104 in a total volume of 100 µl) 
were loaded into the upper chamber and NIH-3T3-conditioned media or media 
containing 5 ng/ml PlGF, 10 ng/ml PlGF, 50 ng/ml VEGF, or 50 ng/ml VEGF plus 
heparin was added to the lower chamber. Assays proceeded for 4 hours at 37oC. 
At completion of the assay, the upper chamber was swabbed to remove residual 
cells and fixed with methanol. Cells on the lower surface of the membrane were 
mounted in DAPI mounting media (Vector Laboratories) and the number of cells 
was determined for five independent fields in triplicate with a 20X objective and 
fluorescence.  
Immunoblotting: Whole cell lysates were prepared by lysis in ice-cold RIPA 
buffer [50 mM Tris (pH 8.0), 150 mM NaCl, 10 mM EDTA, 1% NP-40, 1% 
deoxycholate, 0.1% SDS, 2 mM phenylmethylsulfonyl fluoride (PMSF), and 5 
ug/ml aprotinin, leupeptin, and pepstatin]. Lysates (50 µg) were separated by 
electrophoresis through 8% SDS-PAGE and transferred to 0.2 µm Nitrocellulose 
membrane (Bio-Rad Laboratories). Membranes were blocked in 5% non-fat milk 
in TBS/Tween-20, blotted with the antibodies for FLT-1 (1:500, R&D Systems) or 
actin (1:5000, Sigma) overnight, followed by secondary peroxidase-conjugated 
anti-goat or anti-rabbit antibodies, and detection was by enhanced 
chemiluminescence.  
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Statistical analysis: Data are presented as the mean ± standard error of mean 
(SEM). The Student t-test was used to assess the significance of independent 
experiments. The criterion p < 0.05 was used to determine statistical significance. 
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Figure 1. MiR-10b suppresses expression of VEGF receptor FLT-1. A,B, RT-
PCR of miR-10b (A) and immunoblot of FLT-1 (B) in SUM-159PT cells 
transfected with either miR-10b precursor, non-targeting control miRNA, or 
transfection reagent alone (mock). C, Immunoblot of FLT-1 and NRP2 
expression in MDA-MB-435 cells transfected with either miR-10b precursor, non-
targeting control miRNA, or transfection reagent alone (mock). D, Immunoblot of 
FLT-1 expression in T47D cells transfected with either miR-10b antisense or 
control antisense. 
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Figure 2. FLT-1 promotes breast cancer cell migration and invasion. A, 
Immunoblot of FLT-1 in SUM-159PT cells transfected with FLT-1 siRNA directed 
to the FLT-1 3’UTR or non-targeting control siRNA. B,C, Migration assays of 
SUM-159PT cells towards various chemoattractants, including SFM, NIH-3T3-
conditioned media, PlGF (B), and VEGF (C). D, Migration and Matrigel invasion 
assays of SUM-159PT cells transfected with FLT-1 siRNA or non-targeting 
control siRNA. *, P < 0.05. **, P < 0.0001. Data for migration and invasion assays 
represent means ± SEM from 3 independent experiments. 
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Figure 3. FLT-1 contains a C-T single nucleotide polymorphism in the 
intron region preceeding exon 13. Heterozygous analysis of FLT-1 in SUM-
159PT cells by denaturing HPLC using Transgenomic Surveyor/WAVE 
sequencing technology. 
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CHAPTER IV 
 
GENERAL DISCUSSION 
 
The acquisition of a motile and invasive phenotype is an important step in 
the development of tumors and tumor metastases (Hanahan and Weinberg, 
2000), requiring the abrogation of cell-cell contacts, remodeling of the ECM and 
cell-matrix interactions, and movement of the cell mediated by the actin 
cytoskeleton. To date, the mechanisms of regulation of these processes in breast 
cancer are poorly understood. An understanding of the ability of a carcinoma cell 
to acquire the migratory and invasive capabilities that lead to metastatic disease 
is a key area for identifying mechanisms of cancer progression and preventing 
metastasis in a clinical setting. MiRNAs have the ability to regulate a large 
number of genes simultaneously and thus provide an attractive model for global 
gene regulation during cancer progression (Tavazoie et al., 2008). 
Recent evidence has shown that deregulation of miRNA expression 
correlates with various human cancers, including breast (Calin and Croce, 2006; 
Iorio et al., 2005; Lu et al., 2005). Furthermore, several miRNAs, including miR-
10b, have been found to play a role in cancer cell motility and metastasis  (Burk 
et al., 2008; Huang et al., 2008; Korpal et al., 2008; Tavazoie et al., 2008; Zhu et 
al., 2008). In recent years, several studies have addressed miR-10b in breast 
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cancer with conflicting results. The first study found that miR-10b is 
downregulated in breast cancer and identified miR-10b as one of 15 miRNAs in a 
miRNA signature able to correctly predict the nature of a tissue sample (i.e. 
normal vs. tumor) (Iorio et al., 2005). A later study supported this notion, with the 
finding that miR-10b correlates inversely with breast tumor size and grade (Gee 
et al., 2008). However, the third study was in disagreement, reporting that miR-
10b acts as a pro-metastatic agent in breast cancer via regulation of HoxD10 and 
RhoC (Ma et al., 2007). In direct contradiction to Gee et al. (2008), miR-10b was 
found to correlate significantly with breast cancer cell progression (Ma et al., 
2007). Taken together, the accumulated data suggest that miR-10b may play a 
role in breast cancer progression, but fail to reach a consensus on the role of 
miR-10b in breast cancer. Thus, I sought to examine the function of miR-10b in 
breast cancer cells. In this thesis, I have established the role of miR-10b in 
suppressing breast cancer cell migration and invasion via regulation of GEF 
TIAM1 and decreased activation of the Rho GTPase Rac1. I have also provided 
evidence that miR-10b regulates expression of the VEGF receptor FLT-1 and 
identified a novel role for FLT-1 in promoting breast cancer cell motility. Taken 
together our data suggest that miR-10b provides a novel mechanism for 
suppressing breast cancer cell motility via downregulation of key proteins. 
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MiR-10b Regulation of Cell Migration 
As described in Chapter 2, I have demonstrated that miR-10b suppresses 
both cell migration and invasion using two different aggressive human breast 
carcinoma cell lines. Similarly, inhibition of endogenous miR-10b in a relatively 
non-motile breast carcinoma cell line increased cell migration and invasion. 
These findings indicate that miR-10b functions as a negative regulator of cell 
migration and invasion in breast cancer. 
MiRNAs have the potential to regulate a number of mRNAs 
simultaneously. However, disrupting the miRNA regulation of a single target can 
have significant phenotypic effects (Bartel, 2007). Thus, it is likely that a single 
miR-10b target plays a seminal role in breast cancer cell motility. Examination of 
common miRNA target prediction computer algorithms revealed a multitude of 
targets, including two targets – TIAM1 and FLT-1 – previously implicated in cell 
motility. I have found that miR-10b targets both TIAM1 (Chapter 2) and FLT-1 
(Chapter 3) in breast cancer cell lines. 
Interestingly, miR-10b decreases activation of the Rho GTPase Rac1 
through downregulation of TIAM1. Rac1 functions as a molecular switch, 
promoting cell migration via regulation of the actin cytoskeleton when bound to 
GTP. These results show, for the first time, that Rac1 activation can be regulated 
by a specific miRNA, thereby providing a new dimension to regulation of cell 
motility. 
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Implications for TIAM1 and Rac1 
TIAM1 is a GEF for the Rho GTPases Rac, Rho, and Cdc42. TIAM1 plays 
a dual role in cell motility, promoting cell adhesion in epithelial cell types while 
promoting migration and invasion in other cell types via activation of Rac1 
(Minard et al., 2004). In breast cancer, TIAM1 increases the migratory and 
invasive phenotypes of breast cancer cell lines (Minard et al., 2004). 
Furthermore, increased expression of TIAM1 is closely correlated to the 
invasiveness of breast tumor cells and the degree of progression of breast 
tumors (Adam et al., 2001). However, the regulation of TIAM1 expression in 
breast cancer has not been investigated. As discussed in Chapter 2, miR-10b 
directly downregulates expression of TIAM1 by binding to its 3’UTR. SUM-159PT 
breast cancer cells are dependent on TIAM1 expression for optimal activation of 
Rac1, an important factor in cell motility. Downregulation of TIAM1 in these cells 
results in decreased activation of Rac1. Importantly, cell motility and Rac1 
activation can be rescued by expression of a TIAM1 cDNA lacking the 3’UTR, 
and therefore the miR-10b target site, suggesting that TIAM1 plays a key role in 
miR-10b-induced suppression of cell motility. These data show, for the first time, 
that TIAM1-mediated Rac1 activation and migration/invasion can be regulated by 
a specific miRNA. Furthermore, our findings provide a novel mechanism for the 
regulation of TIAM1 expression in breast cancer. These findings are supported 
by the recent observation that miR-10b expression decreases as a function of 
grade in breast cancer (Gee et al., 2008). 
63 
 
Rac1 activity is tightly controlled by several factors in addition to TIAM1. 
These include GAPs, GDIs, and other GEFs. GAPs, such as RalA binding 
protein 1 (RalBP1), increase the rate of GTP hydrolysis. GDIs bind to GDP-
bound Rac1, thereby inhibiting nucleotide exchange. GEFs – including TIAM1, 
Trio (Triple functional domain (PTPRF interacting)), Son-of-sevenless-1 (Sos-1) 
and Pak-interacting exchange factor β (β-Pix) – stimulate the exchange of GDP 
for GTP, thereby activation Rac1. In addition, Ras family monomeric G-proteins, 
including K-Ras and H-Ras, act as upstream regulators of Rac1, regulating the 
activation states of Rac1 in response to growth factor or cytokine stimulation 
(Bar-Sagi and Hall, 2000; Walsh and Bar-Sagi, 2001). Rac1-dependent migration 
of carcinoma cells in response to chemoattractant or cell surface receptor 
signaling, specifically clustering of β1 integrin, is also regulated by cAMP-
dependent protein kinase (PKA) (O'Connor and Mercurio, 2001). Such an 
extensive level of coordinate regulation of Rac1 activation has important 
implications for the regulation of cancer cell motility. My findings add a new 
dimension to Rac1 activation that involves miRNA. Given that miRNAs can 
regulate numerous targets simultaneously, much remains to be learned about 
Rho GTPases are regulated in cancer. 
In addition to Rac1, TIAM1 also acts as a GEF for Rho and Cdc42. RhoA 
and Cdc42 have been shown to potentiate invasion of fibroblasts (Stam et al., 
1997), however, RhoA can also function to impede cell invasion in invasive 
breast carcinoma due to a reciprocal relationship between RhoA and Rac1 
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activation (Simpson et al., 2004). Furthermore, both Rac and Cdc42 have been 
shown to inhibit Rho activity (Sander et al., 1999). Further investigation is 
necessary to determine whether miR-10b alters the activation status of Cdc42 
and RhoA via TIAM1 or Rac1, and whether crosstalk through shared effectors 
affects cancer cell motility. 
Although TIAM1 has been implicated in breast cancer progression, to date 
no one has examined its expression in breast cancer metastases. It will be 
important to determine whether expression of TIAM1 is maintained in distant 
metastases, and if expression is cancer subtype dependent. Based on my 
findings and others (Adam et al., 2001; Minard et al., 2004), I predict that TIAM1 
expression is maintained in metastases and that TIAM1 plays an important role 
in metastatic spread. 
As a key factor in cell motility, TIAM1 may be a promising target for cancer 
therapeutics. TIAM1 rescues the miR-10b phenotype of decreased cell motility, 
suggesting that TIAM1 is the primary target of miR-10b. Therefore, targeting 
knockdown of TIAM1 in cancer may prove to be an efficacious therapeutic 
strategy. One potential concern is that targeting TIAM1 may disrupt cell-cell 
adhesion in epithelial cells. Data from TIAM1 knockout mice indicate that loss of 
TIAM1 impedes Ras-induced oncogenesis, however, these mice develop, grow 
and reproduce normally (Malliri et al., 2002). This indicates that therapeutics 
directed against TIAM1 may impede breast cancer cell motility without impairing 
epithelial cell-cell adhesion. Further investigation is needed to determine whether 
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knockdown of TIAM1 in vivo gives the same migratory phenotype as expression 
of miR-10b.  
 
Implications for FLT-1 
The VEGF/PlGF receptor FLT-1 has also been implicated in both cell 
motility and breast cancer progression. FLT-1 expression correlates with a high 
risk of metastasis and relapse in both node negative and invasive breast cancer  
(Ghosh et al., 2008; Meunier-Carpentier et al., 2005; Mylona et al., 2007; van 't 
Veer et al., 2002). Furthermore, treatment with anti-FLT-1 antibody or FLT-1-
specific inhibitory peptides suppresses breast tumor growth and metastasis (Bae 
et al., 2005; Luttun et al., 2002; Taylor and Goldenberg, 2007; Wu et al., 2006). 
Collectively, these data suggest that FLT-1 plays an important role in breast 
cancer progression. Although FLT-1 functions to promote cell motility in other 
solid tumors, the function of FLT-1 in breast cancer cell motility has not yet been 
explored. As shown in Chapter 3, FLT-1 promotes both cell migration and 
invasion in SUM-159PT breast cancer cells. FLT-1 knockdown using RNAi 
causes a striking decrease in cell invasion, with a more modest effect on cell 
migration. This suggests that FLT-1 functions primarily to promote invasion 
through the basement membrane and into the surrounding tissue, with a lesser 
role in cell migration through the ECM. To date, one other group has examined 
FLT-1 function in breast cancer, reporting that FLT-1 promotes cell survival via 
an internal autocrine signaling pathway (Lee et al., 2007). My own preliminary 
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observation is that FLT-1 knockdown in SUM-159PT cells has no adverse effects 
on cell survival, although this will need to be verified experimentally by cell 
proliferation assays and Annexin-V/PI staining for flow cytometric study of cell 
death. However, it is possible that the internal autocrine signaling pathway 
previously identified (Lee et al., 2007) may account for ligand-independent 
migration that I observed in these cells. Further investigation to examine the 
localization of FLT-1 in these cells is warranted. If FLT-1 is localized internally in 
SUM-159 cells, it provides an explanation for the failure of VEGF or PlGF to 
stimulate SUM-159 cell migration (Chapter 3) and suggests that FLT-1 
expression may promote a basal level of signaling that contributes to cell motility.  
Expression of miR-10b in SUM-159PT cells causes significant 
downregulation of FLT-1 protein, while inhibition of endogenous miR-10b in T47D 
cells increases FLT-1 expression. These data indicate FLT-1 is a target of miR-
10b and provide a novel mechanism for regulation of FLT-1 expression in breast 
cancer. Furthermore, these data provide evidence that miR-10b regulates 
expression of not one, but two key proteins involved in breast cancer cell motility 
and breast cancer progression. To determine whether FLT-1 is a direct target of 
miR-10b, it will be necessary to perform luciferase reporter assays demonstrating 
the direct interaction of miR-10b with the FLT-1 3’UTR. 
FLT-1, generally believed to be a cell surface receptor, is especially 
attractive as a drug target for blocking breast cancer progression, and is currently 
under investigation as a target in radioimmunotherapy (Lee et al., 2009). In 
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addition, anti-FLT-1 monoclonal antibody IMC-18F1 (Wu et al., 2006) is now in 
Phase I clinical trials in patients with advanced solid tumors who have not 
responded to standard therapy or for whom no standard therapy is available 
(National Cancer Institute Clinical Trials database, 2009). I have shown that FLT-
1 plays a role in cell migration and invasion in breast cancer, however, further 
studies are needed to examine downstream signaling pathways as well as other 
functions of FLT-1 such as cell survival and metastasis. 
 
Other (Novel) miR-10b Targets 
Exploration of other miR-10b targets is warranted to further understand 
the network of targets and signaling pathways regulated by miR-10b. NFAT5 
(nuclear factor of activated T-cells 5) is a putative target of miR-10b that has 
been previously implicated in breast cancer cell motility. NFAT5 is a transcription 
factor that is expressed in invasive human ductal breast carcinomas and 
promotes cellular invasion of both breast and colon cancer cell lines (Jauliac et 
al., 2002). As such, NFAT5 may be another important target regulated by miR-
10b in breast cancer. Overexpression of putative miR-10b target and receptor 
tyrosine kinase EPH receptor A2 (EphA2) is commonly observed in aggressive 
breast cancer and correlates with a poor prognosis (Brantley-Sieders et al., 
2008). Several of these genes have the potential to contribute to the miR-10b 
phenotype. Thus, miR-10b may regulate a multitude of genes simultaneously in 
the suppression of cell motility. Other genes of interest, which may have 
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functions other than cell motility, include putative miR-10b target BACH2 (BTB 
and CNC homology 1, basic leucine zipper transcription factor 2), which is 
upregulated in ovarian cancer (Motamed-Khorasani et al., 2007). 
 
Cooperative Regulation with Other miRNAs 
Interestingly, both TIAM1 and FLT-1 are predicted to be regulated by other 
common miRNAs in addition to miR-10b. These miRNAs include miR-302b and 
miR-17-5p. The function of the miR-302 cluster, which is known to be specifically 
expressed in embryonic stem cells, has not yet been explored in cancer. 
However, miR-17-5p has been found to suppress cell proliferation and function 
as a tumor suppressor in breast cancer (Hossain et al., 2006; Yu et al., 2008). 
These findings suggest that key target proteins such as TIAM1 and FLT-1 may 
be regulated by multiple miRNAs simultaneously. An important goal for the future 
is understanding how miRNAs function as a network, in other words studying the 
coordinate action of multiple miRNAs on a single miRNA target. Coordinate 
action of miR-10b, miR-17-5p, and miR-302 on common targets may be 
necessary for optimal gene regulation during cancer progression. It will be 
important to determine which miRNAs act on TIAM1 and FLT-1, as well as other 
common targets. 
Given that miR-10b contains the same seed sequence as miR-10 family 
member miR-10a, and differs from miR-10a by only a single base pair, it will also 
be important to investigate the role of miR-10a and its targets in breast cancer. 
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MiR-10a is predicted to have many of the same targets as miR-10b and is 
therefore likely to play to a similar role in suppression of breast cancer cell 
motility.  Interestingly, previous studies of miR-10a in breast cancer have shown 
that it regulates HoxD4 in a transcriptional manner (Tan et al., 2009), indicating 
that miRNA control of transcription may be another potential system for gene 
regulation in breast cancer. In addition, miR-10a interacts with the 5' untranslated 
region of mRNAs encoding ribosomal proteins to enhance their translation (Orom 
et al., 2008), thereby providing a novel mechanism for global protein synthesis. It 
will be important to determine whether miR-10b is capable of acting in a similar 
manner to regulate gene expression, as well as whether miR-10a and miR-10b 
act cooperatively to regulate breast cancer cell motility.  
 
Regulation of miR-10b Expression 
MiR-10b is downregulated in breast cancer (Iorio et al., 2005), but the 
regulation of miR-10b itself has not yet been explored. Important questions that 
will need to be answered include when, where, and how miR-10b expression is 
lost during the course of cancer progression. For example, miR-10b expression 
could be downregulated during the oncogenic transformation of a normal breast 
epithelial cell to a cancer cell, or it may be lost during the course of cancer 
progression. If miR-10b is lost during the course of cancer progression, it may be 
lost only at the invasive front or throughout the primary tumor. Future studies 
utilizing fluorescence in situ hybridization (ISH) with locked nucleic acid probes to 
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examine expression of miR-10b in archived specimens will help to resolve these 
questions (Sempere et al., 2007).  
It is also important to identify the mechanism for miR-10b downregulation 
in cancer.  Determining the specific subcellular compartmentalization of the 
precursor and mature forms of miR-10b through ISH may provide insight into the 
modulation of both miR-10b and its targets. Possible mechanisms of regulation 
include defects in miRNA biogenesis, promoter methylation, and transcription 
factor regulation.  
MiR-10b is located within the HoxD gene cluster on chromosome 2 at 
2q31.1. MiRNAs  located in hox clusters have been shown, in general, to inhibit 
more anterior hox genes ("posterior prevalence phenomenon") (Lempradl and 
Ringrose, 2008). HoxD10 has been identified as a miR-10b target (Ma et al., 
2007). However, I was not able to confirm this result. HoxD10 expression is 
progressively reduced in epithelial cells as malignancy increases in breast cancer 
and has been postulated to act as a tumor suppressor (Carrio et al., 2005). 
Therefore, it is possible that highly aggressive SUM-159PT cells may not express 
HoxD10. Given that SUM-149 cells were previously shown by our lab and others 
to express high levels of RhoC (Simpson et al., 2004), it seems unlikely that miR-
10b suppression of HoxD10 in these cells leads to induction of RhoC, as 
reported by Ma et al. (2007). Therefore, the validity of HoxD10 as a target of 
miR-10b will need to be confirmed. However, as a family of transcription factors, 
the HoxD genes may play a role in regulating miR-10b at the transcriptional level, 
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increasing miR-10b transcription in normal tissue and/or repressing transcription 
in cancer. Interestingly, HoxD10 has recently been shown to regulate miR-7 in 
various human cancers (Reddy et al., 2008). In breast cancer, the expression of 
miR-7 is positively regulated by HoxD10, the loss of which increases 
invasiveness. Furthermore, protein levels of the miR-7 target Pak1 are 
progressively upregulated whereas those of miR-7 and its upstream activator 
HoxD10 are progressively downregulated in a cellular model of breast cancer 
progression from low to highly invasive phenotypes (Reddy et al., 2008). It is 
possible that HoxD10 regulates miR-10b in the same manner. Future studies are 
necessary to examine this possibility. 
  
Relevance to Human Breast Cancer 
 I propose that expression of miR-10b is diminished in breast cancer and 
that this change in expression is critical to breast cancer progression. In normal 
breast epithelial cells, miR-10b represses expression of key target proteins, such 
as TIAM1 and FLT-1. In breast tumor cells, expression of miR-10b is decreased, 
thereby releasing inhibition of TIAM1 and FLT-1, allowing these proteins to be 
expressed. Increased expression of TIAM1 activates Rac1, leading to increased 
cell migration and invasion. Increased expression of FLT-1 also contributes to 
increased cell invasion, and to a lesser extent, migration. The ability of these 
cancer cells to migrate through the ECM and invade the basement membrane 
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encasing the tumor increases the probability of local invasion and metastatic 
spread, thereby promoting breast cancer progression.  
Given the finding that miR-10b suppresses breast cancer cell motility, it is 
important to consider the significance of this for clinical breast cancer. All of my 
studies were conducted in vitro, therefore, it will be important to extend future 
studies to in vivo systems, such as xenograft models of breast cancer or a 
transgenic miR-10b knockout, to examine the physiologic relevance of miR-10b 
to breast cancer progression, and specifically to the processes of local invasion 
and metastatic spread. The function of miR-10b as a suppressor of cell motility 
may extend to other solid tumors, such as colon and prostate carcinomas, and 
therefore the efficacy of miR-10b gene therapy may be universal. The 
reconstitution of tumor suppressive miRNA, such as miR-10b, has remarkable 
potential in the treatment of cancer. However, key technical aspects – including 
optimization of selectivity, stability, in vivo delivery, efficacy, and safety – need to 
be investigated before miRNA can be utilized as a successful therapeutic 
strategy. 
MiR-10b may also prove useful in cancer diagnosis. Expression profiling 
of miRNAs has been shown to be a more accurate method of classifying cancer 
subtypes than using the expression profiles of protein-coding mRNAs. Therefore, 
differential expression of certain miRNAs, such as miR-10b, in various tumors 
might become a powerful tool to aid in the diagnosis and treatment of cancer. 
MiR-10b has previously been identified as one of 15 miRNAs in a miRNA 
73 
 
signature able to discriminate between normal breast tissue and breast tumor 
tissue (Iorio et al., 2005), however, the findings regarding miR-10b as a potential 
prognostic marker in breast cancer are controversial (Gee et al., 2008; Ma et al., 
2007). To resolve this discrepancy, it will be important to examine miR-10b 
expression in both primary breast tumors and distant metastases according to 
degree of invasion as well as cancer subtype (i.e. luminal, basal, Her2neu, and 
normal-like).  It is possible that miR-10b plays different roles in these different 
tumor types, and therefore miR-10b may be an effective therapeutic for some 
patients but not others.  
 
Discrepancy with Published Data 
The data on miR-10b function in breast cancer cell lines that I report in this 
thesis conflict with the findings published by Ma et al. (2007). To verify my 
results, I obtained the same miR-10b retroviral plasmid prepared by Ma et al. and 
used for their studies. In addition, I utilized the same cell line, SUM-149, and 
conducted migration assays under the same conditions. Briefly, cells were 
cultured under the same conditions and transduced with a miR-10b retrovirus or 
empty vector control. Migration and invasion assays were conducted on 
uncoated or Matrigel coated transwells, respectively, utilizing serum as the 
chemoattractant. I found that exongenous expression of either a miR-10b 
precursor or a miR-10b retroviral plasmid suppresses the motility of SUM-159PT 
and SUM-149PT cells. In contrast, Ma et al. (2007) observed that exogenous 
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miR-10b enhances the motility of SUM-149PT cells. While I cannot rule out the 
possibility of acquired cell differences, the accumulated data clearly indicate that 
miR-10b suppresses cell migration and invasion in breast carcinoma cells. Given 
this result, it is difficult to reconcile the opposing conclusions regarding miR-10b 
in breast cancer cell motility. However, my data are supported by the recent 
finding that miR-10b correlates inversely with breast tumor size and grade, but 
not with cancer metastasis (Gee et al., 2008).  
Interestingly, I observed that miR-10b is expressed in an epithelial-like, 
non-metastatic cell line, but not in an invasive or aggressive metastatic cell line, 
in direct contrast to previously published results that miR-10b is highly expressed 
only in metastatic breast cancer cells (Ma et al., 2007). T47D cells, a 
differentiated epithelial strain derived from a pleural effusion of infiltrating ductal 
carcinoma (Keydar et al., 1979), express miR-10b. These cells are relatively non-
motile in vitro and non-metastatic in vivo. In contrast, SUM-159PT cells are an 
aggressive triple negative line (ER-/PR-/Her2-) derived from anaplastic 
carcinoma. These miR-10b-null cells are metastatic upon orthotopic injection in 
nude mice (Flanagan et al., 1999). Similarly, miR-10b-null SUM-149PT cells are 
derived from locally invasive inflammatory breast cancer, a particularly lethal 
form of breast cancer. These cells are postulated to undergo metastatic spread 
via a passive mechanism as tumor emboli, but are metastatic nonetheless 
(Hoffmeyer et al., 2005).  
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I also question the purported role of miR-10b in inducing RhoC expression 
because our laboratory had reported previously that SUM-149PT cells, which 
were shown to lack miR-10b expression by both us (Fig. 1) and Ma et al. (2007), 
express relatively high levels of RhoC (Simpson et al., 2004). RhoC is 
overexpressed in breast cancer and has been postulated to be a novel marker 
for aggressive breast carcinomas with metastatic ability (Kleer et al., 2005; Kleer 
et al., 2002), such as the SUM-149PT and SUM-159PT breast cancer cell lines. 
Furthermore, HoxD10 expression is progressively reduced in epithelial cells as 
malignancy increases in breast cancer and has been postulated to act as a tumor 
suppressor (Carrio et al., 2005). I believe it is possible that aggressive, invasive 
breast cancer cell lines such as SUM-149PT and SUM-159PT do not express 
HoxD10 protein. Western blot analysis will be necessary to confirm this 
hypothesis.  
In conclusion, the data presented in the preceding chapters contributes to 
our understanding of the regulation of cell migration and invasion in breast 
cancer. Future research in this area will undoubtedly provide insight into the role 
of miRNAs in breast cancer and perhaps lead to valuable diagnostic tools and 
clinical therapies for breast cancer treatment. 
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APPENDIX 
 
 
 
 
This appendix contains publications to which I have contributed, but that 
are not included in the main body of my thesis.  
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Abstract
Two flavonoids, genistein and apigenin, have been
implicated as chemopreventive agents against prostate
and breast cancers. However, the mechanisms behind
their respective cancer-protective effects may vary
significantly. The goal of this study was to determine
whether the antiproliferative action of these flavonoids
on prostate (DU-145) and breast (MDA-MB-231) cancer
cells expressing only estrogen receptor (ER) B is
mediated by this ER subtype. It was found that both
genistein and apigenin, although not 17B-estradiol, ex-
hibited antiproliferative effects and proapoptotic ac-
tivities through caspase-3 activation in these two cell
lines. In yeast transcription assays, both flavonoids
displayed high specificity toward ERB transactivation,
particularly at lower concentrations. However, in mam-
malian assay, apigenin was found to be more ERB-
selective than genistein, which has equal potency in
inducing transactivation through ERA and ERB. Small
interfering RNA-mediated downregulation of ERB ab-
rogated the antiproliferative effect of apigenin in both
cancer cells but did not reverse that of genistein. Our
data unveil, for the first time, that the anticancer action
of apigenin is mediated, in part, by ERB. The differential
use of ERA and ERB signaling for transaction between
genistein and apigenin demonstrates the complexity
of phytoestrogen action in the context of their anti-
cancer properties.
Neoplasia (2006) 8, 896–904
Keywords: Phytoestrogens, genistein, ERa, apoptosis, cancer chemo-
prevention.
Introduction
Flavonoids present in soy, fruits, and vegetables have been
implicated as chemopreventive agents for a variety of
cancers [1–3]. The best-studied flavonoid is genistein, an
isoflavone abundant in soy. The beneficial effects of dietary
soy are supported by epidemiological observations that
countries with high soy consumption, such as China and
Japan, have lower incidences of prostate and breast
cancers than countries with little or no soy consumption
[4]. In experimental models, dietary genistein reduces the
incidence of prostate [5] and breast cancers [6,7]. Cellular
and molecular mechanisms underpinning the anticancer
effects of genistein cover a broad array of cellular processes,
including suppression of cell growth, angiogenesis, oxidative
stress, and tissue responses to estrogens [8]. Genistein is also
recognized as a phytoestrogen because it binds to estrogen
receptors (ERs) and exhibits both weak estrogenic and anti-
estrogenic activities.
Recently, the antitumor action of another dietary flavonoid,
apigenin (4V,5,7-trihydroxyflavone), has received growing at-
tention. It is abundantly present in leafy plants and vegetables
(e.g., parsley, artichoke, basil, and celery) [9], but its production
from manufacturers comes from extracts of dried flower heads
ofMatricaria chamomilla L. (http://ntp.niehs.nih.gov/ntp/htdocs/
Chem_Background/ExSumPdf/Apigenin.pdf; accessed July 8,
2006). As a nutriceutic, apigenin is most widely used in treat-
ing anxiety and sleep disorders because it has been shown
to possess sedative, antispasmodic, and spasmolytic actions
[10]. The flavonoid also holds great promise as a chemopre-
ventive agent for a variety of cancers. It exhibits significant ac-
tivity against UV-induced DNA damage and thus may protect
against skin cancer [11,12]. It inhibits the growth of a variety of
human cancer cells, including leukemia and breast, colon,
skin, thyroid, and prostate cancers [13,14]. Reported mecha-
nisms associated with its antitumor action include induction
of cell cycle arrest and apoptosis through a tumor necrosis
factor– induced NFnB-mediated apoptosis pathway [14,15],
attenuation of the phosphorylation of epidermal growth factor
receptor and MAP kinase [16], promotion of HER-2/neu degra-
dation [17], and activation of the intrinsic apoptosis pathway
[18,19]. However, the likelihood that apigenin acts as an estro-
gen or antiestrogen has not been considered as a mechanism
mediating its antitumor action.
It is now known that the actions of estrogens, antiestrogens,
and phytoestrogens are mediated by two ER subtypes (ERa
and ERb) whose expression levels vary dramatically among
different organs or cell types [20]. The two receptors regu-
late different sets of biologic functions and incite dissimilar
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responses within the same cell type or tissue. Furthermore, it
has become apparent that the actions of these receptors
vary dramatically, depending on whether they exist alone or
together in a cell [21,22]. Because genistein and other
phytoestrogens have been shown to preferentially use ERbs
over ERas as signaling mediators [23–26], it is reasonable
to anticipate that apigenin exhibits a similar preference
for estrogenicity.
The present study seeks to test the hypothesis that
apigenin-induced cancer cell death is mediated by ERb and
neither by ERa nor androgen receptor. The prostate cancer
cell line DU-145 [27,28] and the breast cancer cell line MDA-
MB-231 [29,30] were chosen as study models because
they both express only ERb. The growth-inhibitory action of
apigenin on these cancer cell lines was examined in the pres-
ence or in the absence of small interfering RNA (siRNA)–
mediated downregulation of the receptor. The transactivation
activities of apigenin at the estrogen-responsive element
(ERE), through ERb, were compared to those mediated
by ERa. Comparisons were also made between apigenin,
17b-estradiol (E2), ICI-182,780 (ICI), and genistein to eluci-
date the estrogenic properties of apigenin.
Materials and Methods
Reagents and Chemicals
Yeast synthetic dropout media were obtained from Clon-
tech (Takara Bio, Palo Alto, CA). All steroids, phytoestrogens,
and etoposide used in this study were purchased from Sigma
(St. Louis, MO). The antiestrogen ICI was kindly supplied
by Zeneca Pharmaceuticals (Cheshire, UK). The Beta-Glo
Assay System was purchased from Promega (Madison, WI).
DNA restriction enzymes were obtained from New England
Biolabs, Inc. (Beverly, MA). Antibodies against human ERa
(sc-8005) or ERb (sc-8974) were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA).
Cell Lines and Culture Conditions
Two human prostate cancer cell lines (DU-145 and PC-3),
a breast cell line (MDA-MB-231), and an embryonic kidney
cell line [human embryonic kidney (HEK) 293] were obtained
from American Type Culture Collection (Manassas, VA).
DU-145 and HEK293 cells were maintained in DMEM sup-
plemented with 10% heat-inactivated fetal calf serum,
nonessential amino acids, and penicillin/streptomycin (Invi-
trogen, Carlsbad, CA). PC-3 and MDA-MB-231 cells were
maintained in DMEM/F12 or MEM-a medium, respectively,
supplemented in the same fashion. Cells were maintained
at 37jC and 5% CO2.
Cell Viability Assay
Cell viability assays were conducted in phenol red–free
medium supplemented with 5% charcoal-stripped serum,
nonessential amino acids, and penicillin/streptomycin. Cells
were plated at 4  103 cells/well in 200 ml of phenol red–free
medium in 96-well plates. Stock solutions of compounds in
dimethyl sulfoxide (DMSO) were stored at 10 mM and mixed
with fresh medium to achieve a final concentration of 10 nM
E2, 1 mM ICI, or 20 mM genistein or apigenin. Cells were
allowed to adhere for 24 hours, at which time the medium was
removed and replaced with media containing one of the
above agents. Control cultures received a medium containing
the vehicle DMSO. Treatment was performed in triplicate and
repeated at 48-hour intervals. On the sixth day, cell viability
was determined by MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium;
inner salt] assay, as described previously [31]. The medium
was aspirated, and the cells were washed once with 200 ml of
Hanks balanced salt solution. Ten microliters of MTS reagent
(CellTiter 96 Aqueous One Solution Reagent; Promega) and
50 ml of medium were added to each well. Following 1 to
4 hours of incubation at 37jC and 5% CO2, absorbance was
recorded by mQuant microplate reader (Biotek, Winooski,
VT) at a wavelength of 490 nm.
Caspase-3 Assay
DU-145 or MDA-MB-231 cells were plated into six-well
plates at 3 105 cells/well in 3 ml of phenol red–free medium
and allowed to attach for 24 hours. Cells were treated with
10 nM E2, 1 mM ICI, and 20 mM etoposide, genistein, or
apigenin. Control cultures were treated with vehicle alone
(DMSO). Treatment time was 48 hours. The presence of
apoptotic cells was determined by measuring caspase-3
using the BD ApoAlert Colorimetric Caspase-3 assay (Clon-
tech), according to the manufacturer’s instructions.
Knockdown of ER by Specific siRNA
Culture conditions for DU-145 (ERa and ERb+) and
MDA-MB-231 (ERa and ERb+) have been described pre-
viously [27,29]. Cells were plated in 96-well or 6-well plates
for MTS assay or RNA extraction, respectively, 1 day before
transfection with siRNA oligonucleotides. Cells were trans-
fected with 50 nM siRNA oligonucleotide using Lipofect-
amine2000 (Invitrogen), according to the manufacturer’s
protocol. siRNA against ERb was purchased from Dharma-
con’s siGENOME SMART pool selection (Lafayette, CO)
and was proven to knock down ERb expression at the mRNA
level by at least 75%. Negative control siRNA, an siCON-
TROL pool, and transfection siRNA control (siTOX) were
included to ensure the specificity and transfection efficiency
of siRNA. Twenty-four hours after transfection, cells were
incubated with 10 or 20 mM apigenin or genistein for another
72 hours and subsequently analyzed for cytotoxicity with
MTS assay. To correct for nonspecific toxic effects of siRNA,
cell viability after treatments with a phytoestrogen (siESR2 +
phytoestrogen or siCTL + phytoestrogen) was normalized
against its respective no-phytoestrogen-treatment control
(siESR2 alone or siCTL alone).
Reverse Transcription–Polymerase Chain Reaction
(RT-PCR) Analysis of ER Transcript Levels
Total RNA was isolated from transfected cells with TRI
reagent (Sigma), according to the manufacturer’s protocol.
The integrity of RNA was confirmed by denaturing gel, as
described previously [32]. Total RNA (4 mg) from each sample
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was reverse-transcribed to cDNA by Superscript II reverse
transcriptase (Invitrogen). Semiquantitative RT-PCR was
performed using Platinum Taq polymerase (Invitrogen) with
ERb-specific primers [33]. The forward and reverse primers
for b-actin have been described previously [27].
Construction of Yeast Strains
The yeast expression (YEpE10) and reporter (YEp-vERE)
plasmids for ERa were kindly supplied by Dr. Tauseef Butt
(LifeSensor, Inc., Malvern, PA). These plasmids were used
to transform the protease-deficient yeast strain BJ2168 ac-
cording to standard protocol [34]. This double-transformant
yeast strain was grown in synthetic dropout medium (TRP
URA). The yeast strain expressing ERb in the presence of an
estrogen-responsive reporter plasmid (YEp-vERE) has re-
cently been described [33]. This double-transformant yeast
strain was grown in synthetic dropout medium (LEUURA).
Yeast-Based Transcription Assays
To study the hormone responsiveness of ERa or ERb,
double yeast transformants carrying an expression plasmid
for ERa or ERb and a reporter plasmid (YEp-vERE) were
selected for ligand-dependent transcriptional activity. Ex-
pression of ERb was analyzed by Western blot analysis [35]
using an N-terminal–specific H-150 polyclonal antibody
(Santa Cruz Biotechnology). Because CUP1 promoter was
moderately leaky in this experiment (data not shown), addi-
tion of copper was not necessary to induce ERb expression.
All selected transformants were grown in a synthetic dropout
medium in a 96-well plate overnight at 30jC, either in the
absence (control) or in the presence of steroids and phyto-
estrogens (0.01 nM–10 mM). A ligand-dependent trans-
activation assay was performed using the Beta-Glo Assay
System (Promega), according to the manufacturer’s protocol.
Induction of the reporter gene (luciferase activity in relative
light units) was measured by the Victor 2 system (Perkin
Elmer, Wellesley, MA).
Transactivation Activity of ERa and ER
in a Mammalian System
Mammalian expression vectors ERa and ERb were gifts
from Dr. Leigh C. Murphy (University of Manitoba, Winnipeg,
Canada) [36]. The luciferase reporter plasmid carrying 3X
vitellogenin ERE was kindly provided by Dr. Craig Jordan
(Fox Chase Cancer Center, Philadelphia, PA) [37].
HEK293 cells at a density of 1.5  104 ml1 were seeded
onto a 24-well plate. Regular culture medium was replaced by
phenol red–free DMEM with 5% charcoal-stripped serum.
The cells were allowed to adopt an estrogen-free envi-
ronment for 48 hours before transfection. Vectors expressing
ERa or ERb + ERE luciferase and b-galactosidase were
transfected into the cells using Lipofectamine Plus (Invitro-
gen). After 24 hours of transfection, E2 (100 pM and 1 nM), ICI
(10 nM and 1 mM), apigenin (100 nM and 1 mM), and genistein
(100 nM and 1 mM) were applied to the culture. In separate
experiments, cells were treated with E2, apigenin, or genis-
tein in the absence or in the presence of the antiestrogen ICI.
Luciferase reporter assay was performed as suggested in
the Bright Glo Luciferase assay kit (Promega) to determine
transactivation activity after 24 hours of treatment with hor-
mones/compounds. Activities of b-galactosidase were mea-
sured by a b-gal assay kit (Promega) to normalize the
transfection efficiency of each well.
Statistical Analysis
Data were expressed as mean ± SD. The statistical
significance of the difference in means among treatment
groups was determined with Systat software (Student ver-
sion 6.0.1; SPSS, Chicago, IL) for one-way ANOVA followed
by Tukey post hoc analyses. P < .05 was considered as a
statistically significant difference between the two groups.
Results
Apigenin and Genistein Suppressed Cell Growth through
Induction of Apoptosis in DU-145 and MDA-MB-231 Cells
The effects of E2 (10 nM), ICI (1 mM), genistein (20 mM), or
apigenin (20 mM) on the growth of DU-145 and MDA-MB-231
in charcoal-stripped medium were examined. At the doses
tested, E2 exerted no impact on the growth (Figure 1A and B)
or the apoptosis (Figure 1C and D) of either cell lines,
whereas ICI induced a small reduction in cell number and
an increase in caspase-3 activation in DU-145 cells when
compared with control vehicle (DMSO), but not in MDA-MB-
231 cells. On the contrary, apigenin and genistein effectively
suppressed the growth of both cell lines. Apigenin was more
effective than genistein in suppressing DU-145 cell growth
(Figure 1A) but exhibited potency equal to that of genistein
in inhibiting MDA-MB-231 proliferation (Figure 1B). The
growth inhibition induced by the two phytoestrogens paral-
leled their abilities to induce caspase-3 activation. Apigenin
and genistein were equally effective in causing caspase-3
activation in both cell lines (Figure 1C and D).
Differential Transcriptional Activation of ERa and ER in
Response to Estrogens and Phytoestrogens in Yeast Cells
The transcriptional activities of E2, ICI, genistein, and
apigenin through ERa and ERb were evaluated in a yeast
system. As expected, E2 was found to transactivate better
through ERa than through ERb (Figure 2A). Interestingly,
although ICI is a well-recognized antagonist in mammalian
cell studies, it behaved as an agonist in yeast cells, trans-
activating more effectively with ERa than with ERb (Figure 2B).
This finding is in agreement with findings in a previous re-
port using yeast reporter assays [38]. In contrast to E2 or ICI,
apigenin and genistein behaved as ERb-selective ligands at
low phytoestrogen concentrations. At higher ligand con-
centrations, they still elicited much higher transactivation ac-
tivities through ERb than through ERa (Figure 2C and D).
Differential Transactivation of ERa and ER in Response
to Estrogens and Phytoestrogens in Mammalian Cells
The HEK293 cell line was chosen as a mammalian
reporter assay system due to its low background as a tran-
scription assay and the absence of endogenous ERa and
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Figure 1. Effects of genistein or apigenin on the proliferation of (A) DU-145 and (B) MDA-MB-231 cells. Cells were treated with 10 nM E2, 1 M ICI, 20 M
genistein, or 20 M apigenin for 72 hours. Control (CTL) cultures were treated with solvent vehicle in a charcoal-stripped serum-supplemented medium. Cell
viability was determined by MTS assay, as described in the Materials and Methods section. (C and D). Induction of relative caspase-3 activity by genistein or
apigenin in (C) DU-145 and (D) MDA-MB-231 cells. Cells were treated with E2, ICI, genistein, and apigenin at the concentrations described above. E2 and
etoposide serve as negative and positive control, respectively, for this experiment. Caspase-3 activities are normalized with respect to the control vehicle (DMSO).
Twenty micromolars of etoposide was used as positive control. Data represent the averages (histograms) of three separate experiments, with the standard
deviation indicated. aStatistically significant difference between the treatment group and the control group (control vehicle for A and B; E2 for C and D) at P < .05.
Figure 2. Differential transcriptional activation of ERa and ER1 in yeast. Yeast strains harboring the expression vectors for ERa (red square) or ER1 (blue
triangle) and the vitellogenin ERE reporter plasmid were incubated with an increasing concentration of E2 (A), ICI (B), apigenin (C), or genistein (D). After 24 hours
of incubation at 30jC, Beta-Glo assays were performed. Luciferase activity (relative light units) was recorded by a luminometer (Victor 2 system). Each point
represents an average of triplicates with standard deviations.
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ERb expression [33]. When physiological concentrations of
E2 (100 pM and 1 nM) were used, this ligand elicited potent
dose-dependent transactivation responses through ERa
(Figure 3A). In contrast, E2 elicited only low levels of trans-
activation through the ERb. Contrary to results obtained in
yeast systems, the antiestrogen ICI was inactive in these
mammalian transcription assays regardless of its action
being mediated by ERa or ERb. In this regard, the results
are consistent with the widely accepted notion that ICI is an
estrogen antagonist for mammalian cells. The two phyto-
estrogens clearly exhibited agonistic actions in mammalian
reporter assays. Apigenin was a weak agonist at a lower
concentration (100 nM) compared to genistein, which
achieved maximal transactivation through ERa and ERb at
the same concentration. At a higher concentration (1 mM),
apigenin exhibited clear ERb selectivity; it induced signifi-
cantly higher transactivation through ERb than through
ERa. Thus, these data appear to corroborate those observed
in yeast-based transcription assays, except for those related
to ICI, which acts as an agonist in yeast assays. Importantly,
all transcriptional activation activities induced by E2, apige-
nin, and genistein through ERb could be attenuated effi-
ciently by the coincubation of cell cultures with 1 mM ICI,
indicating that they were mediated by ERb (Figure 3B).
Similar results were obtained when this experiment was
conducted with ERa expressing HEK293 (data not shown).
ER Plays a Role in Apigenin-Induced Cancer Cell
Growth Inhibition
The relative efficacy of siRNA against ERb (ERb siRNA),
negative control siRNA (siCONTROL pool), and transfection
siRNA control (siTOX) in knocking down ERb transcripts in
transfected cells was determined by RT-PCR. As shown
in Figure 4A, ERb transcripts were reduced by > 85% in
DU-145 and MDA-MB-231 cells, whereas the other siRNA
(siCONTROL pool and siTOX) did not affect the expression
of ERb transcripts when compared to cultures without siRNA
transfection (control cultures were treated with Lipofectamine
alone). Transfection efficiency in these experiments was
estimated as 70%.
Subsequently, DU-145 and MDA-MB-231 cells were ex-
amined for cell viability after treatment with phytoestrogens.
For both cell lines, apigenin (10 and 20 mM) induced a
dose-dependent reduction in cell growth (Figure 4B and C),
whereas genistein caused only cell growth inhibition at the
high dose (20 mM) (Figure 4D and E ). Importantly, the
antiproliferation effects of apigenin on DU-145 and MDA-
MB-231 were effectively abrogated by transfecting the cells
Figure 3. (A) Transcriptional activation of ERa and ER1 in mammalian cells. HEK293 cells were transfected with vectors expressing ERa (red bar) or ER1 (blue
bar), -galactosidase, and a vector carrying 3X ERE luciferase reporter using Lipofectamine Plus, as described in the Materials and Methods section. After
24 hours, cells were treated with E2, ICI, apigenin, genistein, or solvent vehicle (CTL) and subsequently analyzed for luciferase activity. Data represent three
separate experiments with standard deviations. aStatistical significance between the treated group and untreated controls at P < .01. bNo significant difference
between the two groups. (B) Effects of ICI on the ligand responsiveness of ER1 in HEK293 cells were seeded onto 24-well plates and transfected with ER1
expression vector, 3X ERE luciferase reporter, and -galactosidase expression plasmids, as described above. Cells were treated with solvent vehicle (CTL), E2,
genistein, or apigenin in the absence (black bar) or in the presence (white bar) of 1 M ICI and subsequently analyzed for luciferase activity. Data represent three
separate experiments with standard deviation.
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with ERb siRNA (Figure 4B and C), but not by transfection of
siCONTROL (Figure 4B and C), siTOX (data not shown), or
ERa siRNA (data not shown). In contrast, genistein-induced
cancer cell growth suppression was not reversed by ERb
siRNA transfection (Figure 4D and E ).
Discussion
The two flavonoids genistein and apigenin have been
studied extensively for their antitumorigenic activities in var-
ious cancers, including prostate and breast cancers [8,14,15,
39,40]. Although many different mechanisms of action have
been proposed [8,13,16–18,39–42], a connection between
the anticancer effects of these flavonoids and ERb has not
been described. Several reports have demonstrated that
interactions between ERa and ERb could significantly alter
the transactivation activities of each receptor and biologic
outcome [21,22]. Therefore, we have chosen the two cancer
cell lines DU-145 and MDA-MB-231, which express only
ERb [27,29], to compare the antiproliferative effects of two
flavonoids. Furthermore, because transcriptional activities
of a nuclear receptor could be markedly altered by post-
translational protein modification and coregulator interaction
in mammalian cells [43], we have evaluated the transcrip-
tional potentials of these two flavonoids in yeast and mam-
malian reporter assays. Because yeast cells are devoid of
transcription coregulators and most posttranslational protein
modification pathways, basal transcriptional activities could
be obtained for comparison with activities in a mammalian
reporter system (HEK293). In this study, we found that the
exposure of DU-145 or MDA-MB-231 cells to either flavo-
noid elicited suppression of cell growth and activation of
caspase-3—a hallmark of apoptosis. In regard to the con-
centrations of genistein or apigenin used and the extent of
growth inhibition/apoptosis induction in cancer cells, our
findings were consistent with those reported by others
[8,19,39,44–46]. For example, genistein has been reported
to trigger apoptosis in breast cancer through calcium-
dependent and calpain/caspase-12–dependent pathways
[47]. In both yeast and mammalian reporter assays, the two
flavonoids were found to act as agonists at the ERE and to
exhibit ERb selectivity for transactivation when compared to
E2, which transactivates most effectively through the ERa.
Between the two flavonoids, apigenin was found to be more
selective with transactivations by ERb than was genistein,
which was equally potent in eliciting transactivation through
Figure 4. (A) ER1 knockdown experiments in DU-145 and MDA-MB-231 cells. Cells were transfected with 50 nM siRNA against ER1 or scrambled siRNA
(siCONTROL), as described in the Materials and Methods section. After 72 hours of incubation, total RNA was extracted and semiquantitative RT-PCR was
performed using specific primers against ER1 and -actin. Similar results were obtained from two separate experiments. (B–E) Antiproliferation effects of
apigenin or genistein on ER1 knockdown DU-145 and MDA-MB-231 cells. siRNA against ER (siESR2)– and siRNA scrambled control (siCONTROL)–
transfected cells were incubated with 10 or 20 M apigenin (B and C) or genistein (D and E) for 72 hours and subsequently analyzed for cytotoxicity by MTS assay,
as described in the Materials and Methods section. Control groups (Lipofectamine2000) without siRNA transfection were treated with vehicle (CTL). The viability of
the cells with apigenin or genistein treatment (siESR2 + phytoestrogen or siCTL + phytoestrogen) was normalized to values obtained in cultures treated similarly
but without phytoestrogens (siESR2 alone and siCTL alone). The cell viability in each treatment group was calculated as a percentage of the value found in
untreated controls without siRNA transfection. Data represent the average of three separate experiments, with standard deviation indicated. aThe mean of the
treated group was statistically different from that of untreated controls at P < .05. bNo significant difference between the treated group and the untreated control.
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the two ER subtypes. The major contribution of our study,
however, resides in the finding that the antiproliferative/
proapoptotic effect of apigenin is apparently mediated by
ERb, whereas that of genistein, at least in these two cell
models, does not involve the receptor. To the best of our
knowledge, this study, which used siRNA knockdown of ERb,
is the first to demonstrate the involvement of this ER subtype
in the antiproliferative/proapoptotic effect of apigenin.
In DU-145 cell cultures, apigenin-induced growth inhibi-
tion was noticeably greater than that induced by genistein,
whereas in MDA-MB-231 cell cultures, both flavonoids
exhibited comparable potency. Consistent with our previous
observations, E2 was found to exert little effect on the growth
of DU-145 cells, whereas ICI induced a modest inhibitory
action [27]. The action of the antiestrogen on the prostate
cancer cell line was shown to be dependent on ERb [27] and
may involve a crosstalk with the NFnB signaling pathway [48].
Morrissey et al. [18] suggested that apigenin-mediated apop-
tosis in DU-145 may not involve ERs. Their conclusion was
reached based on the cotreatment of apigenin-exposed
DU-145 cells with ICI and their observation of a lack of
attenuation of the apigenin effect. Our findings offer a pos-
sible explanation for their observation. Because ICI could
exhibit its antiproliferative/proapoptotic on DU-145 cells per
se [27], the addition of ICI to apigenin-treated cells would
unlikely block the proapoptotic effects of apigenin. In this
study, our use of siRNA to specifically knock down ERb
proves to be a better approach to demonstrating the involve-
ment of the receptor in apigenin action.
In MDA-MB-231 breast cancer cells, as expected [49], E2
did not stimulate cell growth and ICI had no action on
proliferation/apoptosis. These findings are consistent with
previously reported findings that the lack of ERa in this cell
line makes it insensitive to estrogen stimulation in terms of
cell proliferation. In contrast, both genistein and apigenin are
effective antiproliferative/proapoptotic agents for this ERa
cell line. In the case of apigenin, its action was found to be
mediated by ERb in this study. If our observation in MDA-
MB-231 could be extended to ERa breast cancers, apigenin
might have clinical utility in the chemoprevention of the
recurrence of these cancers [50].
In the present study, we demonstrated that apigenin and
genistein, when compared to E2, exhibit markedly differ-
ent transactivation potencies through the two ER subtypes.
E2 effectively induces ERa-mediated transcription but only
triggers minimal transactivation through ERb. In contrast,
apigenin and genistein are excellent ERb-mediated trans-
activators. This property of the two flavonoids is most notice-
able in yeast reporter assays, which lack modulations from
endogenous transcriptional coregulators or cofactors. Even
in mammalian cell assays (HEK293 cells), both flavonoids
are highly effective in eliciting ERb-mediated transactivation.
A key difference between the two resides in the strong
selectivity of apigenin for ERb-mediated transactivation,
whereas genistein is equally effective in activating ERa-
mediated and ERb-mediated transcription. Collectively, find-
ings from yeast and mammalian reporter assays suggest that
apigenin is an ERb-selective ligand, whereas genistein can
activate both receptor subtypes. This conclusion is corrobo-
rated by a recent report that found genistein to have a higher
binding affinity toward ERa than does apigenin [51].
The differences between these two flavonoids as phytoes-
trogens could be related to several key attributes that define
the mode of estrogen action. Generally speaking, phyto-
estrogens have weak binding affinities for both ER subtypes,
but they bind ERb better than ERa [52]. However, a greater
binding affinity of a phytoestrogen for a specific ER subtype
does not always correlate with its ability to better transacti-
vate gene expression through that receptor [53,54]. Other
important factors that determine selectivity for an ER subtype
include the ability of the phytoestrogen to create a high-
affinity coregulator-binding pocket by the correct positioning
of helix 12 within the ligand-binding domain of the ER–ligand
complex [55]. In this regard, phytoestrogens have been
shown to confer ERb with coregulator-recruiting affinity
higher than that of ERa [23,56]. Although most soy iso-
flavones, including genistein, are believed to exert their ac-
tions primarily through ERb signaling [57,58], recent studies
[59,60] have raised doubts about this assumption. Our data
from HEK293 reporter assays support these doubts as
genistein was found to be equally effective in eliciting trans-
activation through either ER subtype. This lack of selectivity
of genistein for ERb signaling may pose a limit to its use as a
chemopreventive agent for breast cancer because its ERa
activity may post concern for increasing the risk of recurrence
of ERa breast cancers, undesirable uterotrophic activities,
and thromboembolic disorders. It is well established that
estrogen action on the uterus and liver is exclusively me-
diated by ERa signaling [61].
The most intriguing finding of the current study is that the
siRNA-mediated knockdown of ERb blocked only the growth-
inhibitory effect of apigenin—not that of genistein—on
DU-145 and MDA-MB-231 cells. This finding suggests that
the anticancer growth effect of apigenin—but not of genis-
tein—involves ERb. Indeed, pharmacological dosages
of genistein have been shown to trigger cytotoxic activities
through ER-independent pathways, such as inhibition of
tyrosine kinase and topoisomerase [62]. Although apigenin
has been shown to elicit pleiotropic effects on a variety of
pathways that mediate antitumor actions [14–17,19], our re-
port is the first one to associate it with ERb signaling. More
recently, genistein and apigenin have been demonstrated to
act as estrogen agonists in ERa/bMCF-7 and T47-D cells by
acting through ERa [29]. Whether apigenin could suppress
cell growth in other ER+ cancer cell lines remains to be de-
termined as both DU-145 and MDA-MB-231 cell lines ex-
press only ERb but not ERa [27–29]. It has been reported
that ERa can heterodimerize with ERb and alter its trans-
activation activity [21,22]. It is therefore logical to expect
cancer cells that express both ER subtypes to respond to
apigenin in a manner different from what has been demon-
strated in DU-145 and MDA-MB-231 cells. It is surprising
to find that the genistein-induced anticancer cell growth
action in DU-145 and MDA-MB-231 cells was not affected
by siRNA-induced downregulation of ERb. Although the anti-
cancer action of genistein on prostate and breast cancers
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has been widely reported, it remains uncertain whether it is
mediated through ERb. In this study, we showed that, at least
in two cancer cell lines that express only ERb, the anticancer
effects of genistein are mediated through mechanisms not
involving this receptor.
In summary, we have demonstrated the preferred usage
of ERb by apigenin as a mediator in suppressing the growth
of DU-145 and MDA-MB-231 cells. Overall, apigenin, when
compared to genistein, has a much stronger selectivity for
ERb than for ERa. Continued efforts placed on this area of
research might provide important insights on the synthesis
of highly selective ERb agonists for anticancer intervention.
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